POPULARITY
Categories
111 episodes with BLA
38 episodes with BLA
38 episodes with BLA
34 episodes with BLA
45 episodes with BLA
11 episodes with BLA
8 episodes with BLA
13 episodes with BLA
22 episodes with BLA
20 episodes with BLA
9 episodes with BLA
14 episodes with BLA
9 episodes with BLA
20 episodes with BLA
9 episodes with BLA
7 episodes with BLA
6 episodes with BLA
109 episodes with BLA
6 episodes with BLA
94 episodes with BLA
5 episodes with BLA
6 episodes with BLA
5 episodes with BLA
3 episodes with BLA
3 episodes with BLA
3 episodes with BLA
10 episodes with BLA
4 episodes with BLA
5 episodes with BLA
11 episodes with BLA
2 episodes with BLA
9 episodes with BLA
20 episodes with BLA
4 episodes with BLA
4 episodes with BLA
6 episodes with BLA
4 episodes with BLA
2 episodes with BLA
4 episodes with BLA
3 episodes with BLA
55 episodes with BLA
2 episodes with BLA
4 episodes with BLA
4 episodes with BLA
6 episodes with BLA
2 episodes with BLA
5 episodes with BLA
4 episodes with BLA
3 episodes with BLA
5 episodes with BLA
3 episodes with BLA
3 episodes with BLA
44 episodes with BLA
2 episodes with BLA
Dr. Shuvro Roy and Dr. Amanda Piquet discuss a brief overview of stiff person syndrome, as well as the trial and the trial results. Read more about this abstract on the AAN website. Show transcript: Dr. Shuvro Roy: Hi, this is Shuvro Roy from the University of Washington and welcome to today's Neurology Minute. I just wrapped a longer conversation with Amanda Piquet from the University of Colorado Anschutz School of Medicine. We were just talking about the recent Phase 2 trial evaluating Miv-cel Kyverna Therapeutics' anti-CD19 CAR T-cell therapy in patients with Stiff Person Syndrome. Amanda, would you mind taking us through a brief overview of SPS as well as the trial and their trial results? Dr. Amanda Piquet: So Stiff Person Syndrome, or SPS, is a rare disabling autoimmune neurologic disease with a major unmet need. About 80% of patients ultimately lose their mobility and we currently have no FDA approved therapies. Existing treatments like IVIG, rituximab, and plasmapheresis are all used off label, often requiring chronic dosing and frequently failing to stop progression. KYSA-8 is a registrational Phase 2 study of 26 patients with refractory SPS. Patients experienced rapid, statistically significant and clinically meaningful improvement across all primary and secondary endpoints. Primary endpoint was the timed 25-foot walk. And this improved by a median of 46% at 16 weeks. Of patients requiring walking aids at baseline, about two thirds no longer needed them by week 16 to complete that 25-foot walk. Some patients who had struggled to walk were even able to run again after treatment. Another key finding was that all patients discontinued chronic immune therapies and remained off treatment as of the last follow-up. From a safety standpoint, miv-cel was generally well tolerated, with no high grade CRS or ICANS observed. In my opinion, these outcomes are unlike anything we've seen previously with Stiff Person Syndrome and may represent a paradigm shift, not only for SPS, but potentially for other antibody-mediated neurologic diseases more broadly. Dr. Shuvro Roy: Just curious, are there any upcoming implications for the application of this treatment for patients, you think, in the coming year or so? Dr. Amanda Piquet: Kyverna, the company who developed miv-cel, has initiated a rolling BLA with the FDA for potential approval and this would be, if approved, the first CAR-T therapy for SPS. So we're anxiously awaiting the outcome of that process. Dr. Shuvro Roy: Fantastic. Amanda, thank you so much for your time. And if you are intrigued and want to know more details behind the findings in the study as well as a conversation around CAR-T therapy for autoimmune neurologic disease as a whole, I encourage you to check out the Neurology Podcast feed for our full conversation there. Thanks for tuning in.
Dr. Shuvro Roy and Dr. Amanda Piquet discuss a brief overview of stiff person syndrome, as well as the trial and the trial results. Read more about this abstract on the AAN website. Show transcript: Dr. Shuvro Roy: Hi, this is Shuvro Roy from the University of Washington and welcome to today's Neurology Minute. I just wrapped a longer conversation with Amanda Piquet from the University of Colorado Anschutz School of Medicine. We were just talking about the recent Phase 2 trial evaluating Miv-cel Kyverna Therapeutics' anti-CD19 CAR T-cell therapy in patients with Stiff Person Syndrome. Amanda, would you mind taking us through a brief overview of SPS as well as the trial and their trial results? Dr. Amanda Piquet: So Stiff Person Syndrome, or SPS, is a rare disabling autoimmune neurologic disease with a major unmet need. About 80% of patients ultimately lose their mobility and we currently have no FDA approved therapies. Existing treatments like IVIG, rituximab, and plasmapheresis are all used off label, often requiring chronic dosing and frequently failing to stop progression. KYSA-8 is a registrational Phase 2 study of 26 patients with refractory SPS. Patients experienced rapid, statistically significant and clinically meaningful improvement across all primary and secondary endpoints. Primary endpoint was the timed 25-foot walk. And this improved by a median of 46% at 16 weeks. Of patients requiring walking aids at baseline, about two thirds no longer needed them by week 16 to complete that 25-foot walk. Some patients who had struggled to walk were even able to run again after treatment. Another key finding was that all patients discontinued chronic immune therapies and remained off treatment as of the last follow-up. From a safety standpoint, miv-cel was generally well tolerated, with no high grade CRS or ICANS observed. In my opinion, these outcomes are unlike anything we've seen previously with Stiff Person Syndrome and may represent a paradigm shift, not only for SPS, but potentially for other antibody-mediated neurologic diseases more broadly. Dr. Shuvro Roy: Just curious, are there any upcoming implications for the application of this treatment for patients, you think, in the coming year or so? Dr. Amanda Piquet: Kyverna, the company who developed miv-cel, has initiated a rolling BLA with the FDA for potential approval and this would be, if approved, the first CAR-T therapy for SPS. So we're anxiously awaiting the outcome of that process. Dr. Shuvro Roy: Fantastic. Amanda, thank you so much for your time. And if you are intrigued and want to know more details behind the findings in the study as well as a conversation around CAR-T therapy for autoimmune neurologic disease as a whole, I encourage you to check out the Neurology Podcast feed for our full conversation there. Thanks for tuning in.
Péter Magyar musí postupovať podobne ako Orbán, ak chce rozobrať systém, ktorý Fidesz budoval šestnásť rokov, hovorí hungarista Ján Blažek. Magyar po volebnom triumfe narazil na prvú veľkú prekážku. Prezident Tamás Sulyok môže podľa expertov spomaľovať reformy novej vlády, no pokus o jeho odvolanie vyvoláva otázky o stave demokracie v Maďarsku. Dokáže Péter Magyar rozobrať Orbánov systém bez toho, aby sám centralizoval moc?
We love to hear from our listeners. Send us a message.In episode 130 of Cell & Gene: The Podcast, Dr. Naji Gehchan, Chief Medical and Development Officer at Kyverna Therapeutics, joins Host Erin Harris to outline the company's mission to apply CAR T-cell therapy beyond oncology to treat severe autoimmune diseases, highlighting promising Phase 2 data from its investigational therapy, Miv-cel, in stiff person syndrome (SPS). Dr. Gehchan explains that Miv-cel works by deeply depleting pathogenic B cells and enabling a broad immune reset, differentiating it from conventional therapies that require ongoing management. As Kyverna advances a rolling BLA submission, Dr. Gehchan positions this milestone as potentially historic, both for SPS patients and for the broader cell therapy field, signaling an inflection point where CAR T could transform autoimmune disease care in the same way it has oncology.Subscribe to the podcast!Apple | Spotify | YouTubeVisit my website: Cell & GeneConnect with me on LinkedIn
CELÝ DÍL NAJDETE NA https://herohero.co/studion A V RÁMCI KLUBOVÉHO PŘEDPLATNÉHO DENÍKU N https://denikn.cz/podcast-studio-n/ Do Česka dorazil dopis z Bruselu, který znovu otevírá otázku Babišova střetu zájmů. Evropská komise chce další vysvětlení a českým úřadům dala měsíc na reakci. Jak vážný problém to pro Andreje Babiše skutečně je? Reportéři Karolína Blažková a Jan Tvrdoň ve Studiu N vysvětlují, proč je Evropská komise stále nespokojená, co Česku hrozí a jestli opozice dokáže Babišovy problémy politicky využít. V epizodě rozebíráme i aktuální napětí uvnitř vládní koalice ANO, SPD a Motoristů. Dochází už premiérovi trpělivost s trolením Petra Macinky a Filipa Turka? Utrhl se Tomio Okamura se svými sólo akcemi ze řetězu? A vydrží toto spojenectví celé volební období? Podívejte se na celý rozhovor. Celé díly Studia N najdete na platformě Herohero, na webu Deníku N jsou přístupné předplatitelům a předplatitelkám Klubu N. Bezplatné části zveřejňujeme v podcastových aplikacích Spotify, Apple Podcasts, Podbean či na YouTube. Sledovat nás můžete také na Instagramu.
Trong khuôn khổ các hoạt động của Thư viện Quốc gia Pháp BnF (Thư viện François Mitterrand), chương trình hội thảo "Pháp-Việt Nam: Cánh cửa giao thoa văn hóa" đã được khởi xướng từ năm 2017 nhằm giới thiệu các nghiên cứu mới về giao lưu văn hóa giữa Pháp và Việt Nam, với nhiều chủ đề đa dạng, đặc biệt là liên quan đến lịch sử văn hóa và khoa học nhân văn, khoa học xã hội. Các phiên hội thảo, nay là dưới hình thức trực tuyến qua nền tảng Zoom, được tổ chức vào một ngày thứ Năm mỗi tháng. Trong niên khóa 2025-2026, các buổi hội thảo đã đề cập đến những chủ đề rất đa dạng, như "Lịch sử của các nhân viên người Việt Nam và Đông Dương tại Thư viện Quốc gia Pháp qua các tài liệu lưu trữ (1942-1965)", "Sự phát triển của văn hóa phản kháng thực dân công khai ở Sài Gòn thông qua báo chí độc lập (1900-1930)" hay "Các vấn đề và thách thức của cộng đồng Pháp ngữ tại Việt Nam"... Chương trình "Pháp - Việt Nam: Cánh cửa giao thoa văn hóa" niên khóa 2025-2026 đã khép lại vào ngày 21/05/2026, với cuộc hội thảo về chủ đề “Từ điển nhập môn để hiểu về Việt Nam: Một cách tiếp cận văn hóa xã hội” với diễn giả là ông Yves Duchère, một chuyên gia về Đông Nam Á và về Việt Nam, hiện làm việc tại Đại học Trung văn Hồng Kông (Chinese University of Hong Kong), Thâm Quyến, Trung Quốc. Chương trình hội thảo sẽ được mở lại vào tháng 11/2026 cho đến tháng 5/2027. Người khởi xướng và thực hiện chương trình này từ năm 2017 chính là tiến sĩ Nguyễn Giáng Hương, hiện đang phụ trách kho sách Đông Dương tại Thư viện Quốc gia Pháp. Đến niên khóa 2025-2026, cô mời nhà sử học François Guillemot, Viện Khảo cổ học Phương Đông (IAO), đồng tham gia tổ chức. Trả lời RFI Việt ngữ ngày 26/05/2026 tại Thư viện Quốc gia Pháp, cô Nguyễn Giáng Hương cho biết: "Chương trình hội thảo "Pháp - Việt Nam: Cánh cửa giao thoa văn hóa" trong thời gian đầu là nằm trong chương trình hợp tác quốc tế giữa Thư viện Quốc gia Việt Nam, Thư viện Quốc gia Pháp và trường Đại học Sư phạm Cao cấp - ENS Paris. Trong những năm đầu, chương trình này được tổ chức ngay tại trường ENS, với hình thức là mời một diễn giả tham gia thuyết trình mỗi tháng một lần và chương trình kéo dài từ tháng 10 đến tháng 5 hoặc tháng 6. Lý do đầu tiên mà chúng tôi có ý tưởng làm chương trình séminaire (hội thảo) này là khi mà chúng tôi bắt đầu triển khai dự án số hóa kho sách Đông Dương. Vì vậy tên gọi của chuỗi hội thảo này bắt đầu bằng France - Việt Nam. Cổng thông tin của Thư viện Quốc gia Việt Nam và Thư viện Quốc gia Pháp cũng bắt đầu bằng chữ France - Việt Nam. Trong những buổi đầu tiên, nhất là chương trình của năm đầu, chúng tôi tập trung vào các mảng khác nhau về kho sách Đông Dương, nhằm tạo được hiệu ứng về về truyền thông, cũng như gây sự chú ý cho cộng đồng khoa học. Sau đó chương trình được tiếp nối bằng các bài thuyết trình khác và ngày càng được mở rộng, đầu tiên là chương trình được sự quan tâm của cộng đồng nghiên cứu quốc tế, sau đó có những tác giả hay những nhà nghiên cứu cũng tự đề xuất những ý tưởng cũng như những bài thuyết trình mới. Chúng tôi cố gắng duy trì cho đến ngày hôm nay. Kết quả vượt qua cả sự mong đợi là chương trình đã được sự đón nhận rất rộng rãi của các học giả cũng như những người quan tâm về giao lưu văn hóa Việt - Pháp. Chương trình của chúng tôi luôn duy trì một lượng khán thính giả nhất định. Từ khủng hoảng Covid, chúng tôi đã mở rộng chương trình theo hình thức trực tuyến online, thì cũng có một điều hay là mình có thể đón nhận được các thính giả từ nước ngoài, ở Việt Nam, ở Mỹ, hay ở các nước khác của châu Âu. Thứ hai là chúng tôi cũng cố gắng mời các diễn giả ở những nước khác nhau và từ nhiều lĩnh vực khác nhau về khoa học xã hội và nhân văn, qua đó giúp chúng tôi có những góc nhìn khác nhau của các tác giả. Có thể là về cùng một lĩnh vực nhưng góc nhìn của một diễn giả ở châu Á sẽ khác với một diễn giả ở Pháp hay một diễn giả ở Mỹ. Chương trình này đã tạo nên một diễn đàn để các nhà nghiên cứu có thể đối thoại với nhau và chúng tôi cũng rất là cởi mở khi có những người không phải trong ngành nhưng quan tâm, hoặc thậm chí những nhân chứng có thể tham gia và có thể kể câu chuyện của riêng mình." Theo lời Nguyễn Giáng Hương, những bài thuyết trình trong khuôn khổ chương trình hội thảo "Pháp -Việt Nam: Cánh cửa giao thoa văn hóa" hiện đã được đưa lên một trang web để mọi người có tham khảo dễ dàng: "Thời gian trước thì tôi có xin một số diễn giả cho dùng lại hoặc là công bố bài thuyết trình của họ. Tôi cũng đã lập ra một website riêng của chương trình này, cũng có tên là "France Vietnam: Le portail entre les cultures", (Pháp - Việt Nam: Cánh cửa giao thoa văn hóa). Dĩ nhiên hiện nay nó vẫn ở dạng như một blog còn hơi thô sơ. Dự định trong tương lai thì có thể sẽ tuyển lựa những bài hay nhất để chúng ta làm một công trình. Thực ra là trước đây, trong một số năm chúng tôi có điều kiện về mặt tài chính cũng như nhân lực để làm hội thảo tổng kết lại một năm thuyết trình. Từ những hội thảo đó thì chúng tôi cũng đã ra được hai ấn bản đúc kết lại những bài thuyết trình của các các diễn giả trong năm." Thư viện số Pháp-Việt : 2.000 tài liệu đặc sắc làm cầu nối giữa di sản Pháp-Việt Thư viện Quốc gia Pháp còn có một thư viện số song ngữ Pháp-Việt, quy tụ những tài liệu phản ánh những tương tác văn hóa, lịch sử, thuộc địa và khoa học giữa hai nước từ thế kỷ 17 đến năm 1954. Ra đời từ sự hợp tác giữa Thư viện Quốc gia Pháp và Thư viện Quốc gia Việt Nam (nay có sự tham gia của Trung tâm Hợp tác Quốc tế Nghiên cứu Nông nghiệp vì Phát triển - CIRAD), thư viện này là một phần của bộ sưu tập Di sản Chung, minh chứng cho mối quan hệ giữa Pháp và thế giới qua nhiều thế kỷ. Thư viện số Pháp-Việt đóng vai trò là cầu nối giữa di sản Pháp và Việt Nam, quy tụ hơn 2.000 tài liệu đặc sắc, tất cả đều có thể được truy cập toàn bộ. Thư viện bao gồm một bộ sưu tập đa dạng các tài liệu in ấn, bản thảo, bản đồ, tranh vẽ và ảnh chụp, được lấy từ các bộ sưu tập của Pháp và Việt Nam. Ngoài ra, khoảng hai mươi văn bản gốc do các chuyên gia, nhà nghiên cứu và người phụ trách bảo tàng người Pháp và Việt Nam giúp người đọc hiểu biết hiểu biết sâu sắc hơn nội dung và bối cảnh của các tài liệu đó. Đối với Nguyễn Giáng Hương, thư viện số Pháp-Việt có vai trò rất quan trọng giúp hiểu được toàn cảnh về xã hội, đời sống văn hóa, nghệ thuật và tri thức của Việt Nam thời kỳ Đông Dương: "Thư viện quốc gia tức là thư viện lưu trữ tất cả những di sản của một quốc gia, nhưng thực ra Thư viện Quốc gia Pháp còn lưu trữ những di sản của nhân loại, trong đó lịch sử của Việt Nam cũng nằm trong dòng chảy của nhân loại. Cụ thể, trong trường hợp Việt Nam với Pháp thì lịch sử chung đã có từ nhiều thế kỷ nay. Vì vậy mà cuốn sách đầu tiên có thể đánh dấu sự tồn tại của tiếng Việt ở thư viện này có lẽ là quyển từ điển Việt - Bồ - La. Cuốn từ điển này từ thế kỷ thứ 16 đã được coi như là cuốn sách đầu tiên. Sau đó Thư viện Quốc gia Pháp cũng thu nhận qua nhiều nguồn khác nhau những sách không chỉ là song ngữ mà có cả sách bằng tiếng Việt, thậm chí là bằng chữ Hán, chữ Nôm của một số nhà viễn du Pháp ngày xưa khi trở về họ mang lại một số văn bản mà họ có được và họ tặng lại cho thư viện. Nói chung có rất nhiều tổ chức nghiên cứu về Việt Nam cho sách và sau đấy thì số lượng sách về Việt Nam mà bằng tiếng Việt tới ngày càng nhiều, nhất là kể từ năm 1922, khi có luật về nộp lưu chiểu ở Đông Dương. Thế là hiện nay, kho sách Đông Dương bằng tiếng Việt là có trên 12.000 ấn bản. Đó là tính riêng về sách thôi. Còn số lượng về báo chí thì cũng độ khoảng vài chục ngàn đầu báo. Chúng ta phải biết mỗi đầu báo là có thể là có nhiều số báo. Số lượng báo rất nhiều. Ấy là chưa kể các bưu ảnh và tất cả nhiều nhiều loại khác nữa. Thậm chí ngày nay, những tư liệu về âm thanh, về hình ảnh liên quan đến Việt Nam cũng có ở Thư viện Quốc gia Pháp. Tức là liên quan đến Việt Nam hoặc Đông Dương thì mình có những tư liệu bằng tiếng Việt, bằng tiếng Pháp và bằng những ngôn ngữ khác nữa. Nó có vai trò rất quan trọng trong việc nghiên cứu và tìm hiểu Việt Nam nói chung và mối quan hệ Việt - Pháp nói riêng. Kho sách, đặc biệt là kho sách Đông Dương, mang lại cho chúng ta một cái nhìn toàn cảnh về xã hội Việt Nam ở thời kỳ Đông Dương, về đời sống văn hóa, nghệ thuật và tri thức của Việt Nam thời kỳ đó. Đấy là một mảng sách vô cùng quan trọng."
Trong khuôn khổ các hoạt động của Thư viện Quốc gia Pháp BnF (Thư viện François Mitterrand), chương trình hội thảo "Pháp-Việt Nam: Cánh cửa giao thoa văn hóa" đã được khởi xướng từ năm 2017 nhằm giới thiệu các nghiên cứu mới về giao lưu văn hóa giữa Pháp và Việt Nam, với nhiều chủ đề đa dạng, đặc biệt là liên quan đến lịch sử văn hóa và khoa học nhân văn, khoa học xã hội. Các phiên hội thảo, nay là dưới hình thức trực tuyến qua nền tảng Zoom, được tổ chức vào một ngày thứ Năm mỗi tháng. Trong niên khóa 2025-2026, các buổi hội thảo đã đề cập đến những chủ đề rất đa dạng, như "Lịch sử của các nhân viên người Việt Nam và Đông Dương tại Thư viện Quốc gia Pháp qua các tài liệu lưu trữ (1942-1965)", "Sự phát triển của văn hóa phản kháng thực dân công khai ở Sài Gòn thông qua báo chí độc lập (1900-1930)" hay "Các vấn đề và thách thức của cộng đồng Pháp ngữ tại Việt Nam"... Chương trình "Pháp - Việt Nam: Cánh cửa giao thoa văn hóa" niên khóa 2025-2026 đã khép lại vào ngày 21/05/2026, với cuộc hội thảo về chủ đề “Từ điển nhập môn để hiểu về Việt Nam: Một cách tiếp cận văn hóa xã hội” với diễn giả là ông Yves Duchère, một chuyên gia về Đông Nam Á và về Việt Nam, hiện làm việc tại Đại học Trung văn Hồng Kông (Chinese University of Hong Kong), Thâm Quyến, Trung Quốc. Chương trình hội thảo sẽ được mở lại vào tháng 11/2026 cho đến tháng 5/2027. Người khởi xướng và thực hiện chương trình này từ năm 2017 chính là tiến sĩ Nguyễn Giáng Hương, hiện đang phụ trách kho sách Đông Dương tại Thư viện Quốc gia Pháp. Đến niên khóa 2025-2026, cô mời nhà sử học François Guillemot, Viện Khảo cổ học Phương Đông (IAO), đồng tham gia tổ chức. Trả lời RFI Việt ngữ ngày 26/05/2026 tại Thư viện Quốc gia Pháp, cô Nguyễn Giáng Hương cho biết: "Chương trình hội thảo "Pháp - Việt Nam: Cánh cửa giao thoa văn hóa" trong thời gian đầu là nằm trong chương trình hợp tác quốc tế giữa Thư viện Quốc gia Việt Nam, Thư viện Quốc gia Pháp và trường Đại học Sư phạm Cao cấp - ENS Paris. Trong những năm đầu, chương trình này được tổ chức ngay tại trường ENS, với hình thức là mời một diễn giả tham gia thuyết trình mỗi tháng một lần và chương trình kéo dài từ tháng 10 đến tháng 5 hoặc tháng 6. Lý do đầu tiên mà chúng tôi có ý tưởng làm chương trình séminaire (hội thảo) này là khi mà chúng tôi bắt đầu triển khai dự án số hóa kho sách Đông Dương. Vì vậy tên gọi của chuỗi hội thảo này bắt đầu bằng France - Việt Nam. Cổng thông tin của Thư viện Quốc gia Việt Nam và Thư viện Quốc gia Pháp cũng bắt đầu bằng chữ France - Việt Nam. Trong những buổi đầu tiên, nhất là chương trình của năm đầu, chúng tôi tập trung vào các mảng khác nhau về kho sách Đông Dương, nhằm tạo được hiệu ứng về về truyền thông, cũng như gây sự chú ý cho cộng đồng khoa học. Sau đó chương trình được tiếp nối bằng các bài thuyết trình khác và ngày càng được mở rộng, đầu tiên là chương trình được sự quan tâm của cộng đồng nghiên cứu quốc tế, sau đó có những tác giả hay những nhà nghiên cứu cũng tự đề xuất những ý tưởng cũng như những bài thuyết trình mới. Chúng tôi cố gắng duy trì cho đến ngày hôm nay. Kết quả vượt qua cả sự mong đợi là chương trình đã được sự đón nhận rất rộng rãi của các học giả cũng như những người quan tâm về giao lưu văn hóa Việt - Pháp. Chương trình của chúng tôi luôn duy trì một lượng khán thính giả nhất định. Từ khủng hoảng Covid, chúng tôi đã mở rộng chương trình theo hình thức trực tuyến online, thì cũng có một điều hay là mình có thể đón nhận được các thính giả từ nước ngoài, ở Việt Nam, ở Mỹ, hay ở các nước khác của châu Âu. Thứ hai là chúng tôi cũng cố gắng mời các diễn giả ở những nước khác nhau và từ nhiều lĩnh vực khác nhau về khoa học xã hội và nhân văn, qua đó giúp chúng tôi có những góc nhìn khác nhau của các tác giả. Có thể là về cùng một lĩnh vực nhưng góc nhìn của một diễn giả ở châu Á sẽ khác với một diễn giả ở Pháp hay một diễn giả ở Mỹ. Chương trình này đã tạo nên một diễn đàn để các nhà nghiên cứu có thể đối thoại với nhau và chúng tôi cũng rất là cởi mở khi có những người không phải trong ngành nhưng quan tâm, hoặc thậm chí những nhân chứng có thể tham gia và có thể kể câu chuyện của riêng mình." Theo lời Nguyễn Giáng Hương, những bài thuyết trình trong khuôn khổ chương trình hội thảo "Pháp -Việt Nam: Cánh cửa giao thoa văn hóa" hiện đã được đưa lên một trang web để mọi người có tham khảo dễ dàng: "Thời gian trước thì tôi có xin một số diễn giả cho dùng lại hoặc là công bố bài thuyết trình của họ. Tôi cũng đã lập ra một website riêng của chương trình này, cũng có tên là "France Vietnam: Le portail entre les cultures", (Pháp - Việt Nam: Cánh cửa giao thoa văn hóa). Dĩ nhiên hiện nay nó vẫn ở dạng như một blog còn hơi thô sơ. Dự định trong tương lai thì có thể sẽ tuyển lựa những bài hay nhất để chúng ta làm một công trình. Thực ra là trước đây, trong một số năm chúng tôi có điều kiện về mặt tài chính cũng như nhân lực để làm hội thảo tổng kết lại một năm thuyết trình. Từ những hội thảo đó thì chúng tôi cũng đã ra được hai ấn bản đúc kết lại những bài thuyết trình của các các diễn giả trong năm." Thư viện số Pháp-Việt : 2.000 tài liệu đặc sắc làm cầu nối giữa di sản Pháp-Việt Thư viện Quốc gia Pháp còn có một thư viện số song ngữ Pháp-Việt, quy tụ những tài liệu phản ánh những tương tác văn hóa, lịch sử, thuộc địa và khoa học giữa hai nước từ thế kỷ 17 đến năm 1954. Ra đời từ sự hợp tác giữa Thư viện Quốc gia Pháp và Thư viện Quốc gia Việt Nam (nay có sự tham gia của Trung tâm Hợp tác Quốc tế Nghiên cứu Nông nghiệp vì Phát triển - CIRAD), thư viện này là một phần của bộ sưu tập Di sản Chung, minh chứng cho mối quan hệ giữa Pháp và thế giới qua nhiều thế kỷ. Thư viện số Pháp-Việt đóng vai trò là cầu nối giữa di sản Pháp và Việt Nam, quy tụ hơn 2.000 tài liệu đặc sắc, tất cả đều có thể được truy cập toàn bộ. Thư viện bao gồm một bộ sưu tập đa dạng các tài liệu in ấn, bản thảo, bản đồ, tranh vẽ và ảnh chụp, được lấy từ các bộ sưu tập của Pháp và Việt Nam. Ngoài ra, khoảng hai mươi văn bản gốc do các chuyên gia, nhà nghiên cứu và người phụ trách bảo tàng người Pháp và Việt Nam giúp người đọc hiểu biết hiểu biết sâu sắc hơn nội dung và bối cảnh của các tài liệu đó. Đối với Nguyễn Giáng Hương, thư viện số Pháp-Việt có vai trò rất quan trọng giúp hiểu được toàn cảnh về xã hội, đời sống văn hóa, nghệ thuật và tri thức của Việt Nam thời kỳ Đông Dương: "Thư viện quốc gia tức là thư viện lưu trữ tất cả những di sản của một quốc gia, nhưng thực ra Thư viện Quốc gia Pháp còn lưu trữ những di sản của nhân loại, trong đó lịch sử của Việt Nam cũng nằm trong dòng chảy của nhân loại. Cụ thể, trong trường hợp Việt Nam với Pháp thì lịch sử chung đã có từ nhiều thế kỷ nay. Vì vậy mà cuốn sách đầu tiên có thể đánh dấu sự tồn tại của tiếng Việt ở thư viện này có lẽ là quyển từ điển Việt - Bồ - La. Cuốn từ điển này từ thế kỷ thứ 16 đã được coi như là cuốn sách đầu tiên. Sau đó Thư viện Quốc gia Pháp cũng thu nhận qua nhiều nguồn khác nhau những sách không chỉ là song ngữ mà có cả sách bằng tiếng Việt, thậm chí là bằng chữ Hán, chữ Nôm của một số nhà viễn du Pháp ngày xưa khi trở về họ mang lại một số văn bản mà họ có được và họ tặng lại cho thư viện. Nói chung có rất nhiều tổ chức nghiên cứu về Việt Nam cho sách và sau đấy thì số lượng sách về Việt Nam mà bằng tiếng Việt tới ngày càng nhiều, nhất là kể từ năm 1922, khi có luật về nộp lưu chiểu ở Đông Dương. Thế là hiện nay, kho sách Đông Dương bằng tiếng Việt là có trên 12.000 ấn bản. Đó là tính riêng về sách thôi. Còn số lượng về báo chí thì cũng độ khoảng vài chục ngàn đầu báo. Chúng ta phải biết mỗi đầu báo là có thể là có nhiều số báo. Số lượng báo rất nhiều. Ấy là chưa kể các bưu ảnh và tất cả nhiều nhiều loại khác nữa. Thậm chí ngày nay, những tư liệu về âm thanh, về hình ảnh liên quan đến Việt Nam cũng có ở Thư viện Quốc gia Pháp. Tức là liên quan đến Việt Nam hoặc Đông Dương thì mình có những tư liệu bằng tiếng Việt, bằng tiếng Pháp và bằng những ngôn ngữ khác nữa. Nó có vai trò rất quan trọng trong việc nghiên cứu và tìm hiểu Việt Nam nói chung và mối quan hệ Việt - Pháp nói riêng. Kho sách, đặc biệt là kho sách Đông Dương, mang lại cho chúng ta một cái nhìn toàn cảnh về xã hội Việt Nam ở thời kỳ Đông Dương, về đời sống văn hóa, nghệ thuật và tri thức của Việt Nam thời kỳ đó. Đấy là một mảng sách vô cùng quan trọng."
Tridsať rokov pôsobenia Blanky Lehotskej na Prírodovedeckej fakulte Univerzity Komenského zahŕňa monitoring a praktickú ochranu netopierov, obojživelníkov, ale aj iných druhov živočíchov, rastlín alebo biotopov. Málokto však vie, že zanietená environmentalistka je aj čerstvou Osobnosťou Bratislavy a k jej koníčkom patrí riešenie a tvorba sudoku a logických úloh. Počúvajte Nočnú pyramídu s Blaženou Bóoczovou. | Hostka: Blanka Lehotská (ochranárka a pedagogička na Prírodovedeckej fakulte UK). | Moderuje: Blažena Bóoczová. | Tolkšou Nočná pyramída pripravuje Slovenský rozhlas, Rádio Slovensko, SRo1.
Hostem čtvrtečního vydání Desítky Pavla Horvátha byl fotbalový brankář Tomáš Grigar. Kdo hlídá výživu u brankářů? Jak vzpomíná na první ligový zápas? Jak vzpomíná na společné angažmá s Jaromírem Blažkem? Proč se nikdy nepřestěhoval do Teplic, kde působil patnáct let? Jak se ohlíží za angažmá v pražské Spartě? Jaké zápasy mu už navždy zůstanou v paměti? Poslechněte si oblíbenou talkshow.
ਐਤਵਾਰ ਨੂੰ ਪਾਕਿਸਤਾਨ ਦੇ ਦੱਖਣ-ਪੱਛਮੀ ਸ਼ਹਿਰ ਕੁਏਟਾ ਵਿੱਚ ਇੱਕ ਆਤਮਘਾਤੀ ਹਮਲਾਵਰ ਨੇ ਵਿਸਫੋਟਕਾਂ ਨਾਲ ਭਰੀ ਕਾਰ ਨੂੰ ਉਸ ਸਮੇਂ ਰੇਲਵੇ ਟ੍ਰੈਕ ਦੇ ਨੇੜੇ ਉਡਾ ਦਿੱਤਾ ਜਦੋਂ ਉੱਥੋਂ ਇੱਕ ਯਾਤਰੀ ਰੇਲ-ਗੱਡੀ ਲੰਘ ਰਹੀ ਸੀ। ਇਸ ਹਮਲੇ ਵਿੱਚ ਕਈ ਲੋਕਾਂ ਦੀ ਮੌਤ ਹੋ ਗਈ ਅਤੇ 70 ਤੋਂ ਵੱਧ ਲੋਕ ਜ਼ਖ਼ਮੀ ਹੋ ਗਏ। ਪਾਕਿਸਤਾਨ ਦੀ ਕੇਂਦਰੀ ਸਰਕਾਰ ਤੋਂ ਅਜ਼ਾਦੀ ਦੀ ਮੰਗ ਕਰਨ ਵਾਲੇ ਪਾਬੰਦੀਸ਼ੁਦਾ ਸੰਗਠਨ ਬਲੋਚ ਲਿਬਰੇਸ਼ਨ ਆਰਮੀ (BLA) ਨੇ ਇਸ ਹਮਲੇ ਦੀ ਜ਼ਿੰਮੇਵਾਰੀ ਲਈ ਹੈ। ਇਸ ਤੋਂ ਇਲਾਵਾ ਸੁਣੋ ਪਾਕਿਸਤਾਨ ਨਾਲ ਜੁੜੀਆਂ ਹੋਰ ਅਹਿਮ ਖ਼ਬਰਾਂ ਇਸ ਪੌਡਕਾਸਟ ਵਿੱਚ।
Una Gjerde og Gjertrud Louise Laurell har invitert forfatter og selvproklamert Toni Morrison-fan Maria Kjos Fonn for å snakke om romanen Jazz. Selve musikksjangeren figurerer ikke i boka, men Morrison selv har sagt at hun vil skrive bøker som jazzmusikk. Lytt for å finne ut hva det betyr! Una Gjerde og Gjetrud Louise Laurell har tidligere skrevet om Toni Morrisons mest berømte roman, Beloved, i deres faste nobelprisspalte i BLA 3/26. Medvirkende: Una Gjerde, Gjertrud Louise Laurell og Maria Kjos Fonn. Produsent: Jakob Meijers Kippersund Nesdal Samtalen er et opptak fra et arrangement på Becco i Oslo, støttet av Kulturrådet.
Samkvæmt nýjustu tölum Hagstofunnar hefur fæðingartíðni aldrei mælst lægri hér á landi. Árið 2025 fæddust að meðaltali 1,56 börn á hverja konu. Fyrir aðeins rúmum áratug hafði sú tala aldrei farið niður fyrir 1,93 börn. Að óbreyttu þýðir þessi fæðingartíðni fólksfækkun. Ingólfur Bjarni Sigfússon fjallar um þetta og talar við Ara Klæng Jónsson ogSigríði Ingibjörgu Ingadóttur. Blikur eru á lofti í heimi fjölmiðla og fréttamennsku í henni veröld, þar sem valdhafar, glæpagengi, stórfyrirtæki, dóms- og löggæslustofnanir vinna leynt og ljóst að því að skerða tjáningar- og fjölmiðlafrelsi. Góðu fréttirnar fyrir okkur eru þær að Ísland færist upp um 5 sæti á nýútgefnum lista yfir fjölmiðlafrelsi í ríkjum heims. Það eru góðar fréttir, sem segja þó ekki alla söguna. Ævar Örn Jósepsson talar við Sigríði Dögg Auðunsdóttur, formann Blaðamannafélags Íslands. Umsjón: Ævar Örn Jósepsson Tæknimaður: Kári Guðmundsson
Bítið á Bylgjunni með Heimi, Lilju og Ómari. Guðmundur Ármann Pétursson, formaður Þroskahjálpar, ræddi við okkur um málefni fatlaðs fólks og síðuna flokkahjalp.is. Soffía Ámundadóttir, íbúi í Suðurhlíðum Reykjavíkur, ræddi við okkur um óánægju íbúa með líkbrennsluna. Blaðamennirnir Jakob Bjarnar Grétarsson og Stefán Einar Stefánsson fóru yfir það helsta. Hannes Jónsson, framkvæmdastjóri KKÍ, ræddi körfuboltann og evrópska körfuboltaþingið. Helgi Steinar Gunnlaugsson, blaðamaður Viðskiptablaðsins og sérfræðingur í Kína, ræddi heimsókn Donald Trump til Kína. Kolbrún Ósk Pétursdóttir og Hannes Sasi ræddu Hamingjuhlaupið.
Slovensko mladinsko gledališče sezono 2025/26 sklepa s predstavo Ne Carmen! Uprizoritev izhaja iz novele Prosperja Mériméeja, po kateri je bil napisan libreto za opero, ki jo je v drugi polovici 19. stoletja zložil skladatelj Georges Bizet. Uprizoritev v režiji Zane Hoxha zaokroža sodobna in problemska predelava Bizetove glasbe, v živo izvajana na klavirju. Predstavo si je ogledala Petra Tanko. Igralska zasedba: Lina Akif, Daša Doberšek, Nataša Keser, Boris Kos, Klemen Kovačič, Anja Novak, Maruša Oblak, Ivan Peternelj, Blaž Šef, Stane Tomazin, pianist Jože Šalej Režija: Zana Hoxha, dramaturgija: Urška Brodar, glasba: Liburn Jupolli, aranžmaji in korepeticija: Jože Šalej, elektroakustična glasba in oblikovanje zvoka: Gašper Torkar, koreografija: Lada Petrovski Ternovšek, scenografija: Dunja Zupančič, kostumografija: Jelena Proković, oblikovanje svetlobe: Borut Bučinel, oblikovanje maske: Nathalie Horvat, asistentka režije: Mojca Madon. Produkcija Slovensko mladinsko gledališče, sezona 2025/26
Ko dom ne pomeni več varnega zavetja, se lahko obrnete na Društvo SOS telefon. Žrtve psihičnega, ekonomskega, spolnega in fizičnega nasilja lahko pokličete na telefonsko številko, kjer ponujajo zaupen pogovor – psihosocialno podporo pa tudi informacije o oblikah pomoči, prijavi nasilja in podobno. Tak klic je morda začetek izstopa iz kroga nasilja, njegovo nadaljevanje pa je lahko tudi umik v zatočišča oziroma tako imenovane varne hiše. Več v četrtkovem Svetovalnem servisu z zaposleno v Društvu SOS telefon Blažko Margon Baloh.
Hart er sótt að frelsi og sjálfstæði fjölmiðla í heiminum. Stjórnvöld og stórfyrirtæki, auðkýfingar og einvaldar, glæpagengi og löggæslustofnanir víða um heim taka þátt í þessari aðför og sækist hún giska vel. Þannig reiknast sérfræðingum alþjóðlegu V-Dem - rannsóknastofnunarinnar í lýðræðismálum, sem er með höfuðstöðvar sínar í Gautaborgarháskóla, svo til að fjölmiðlafrelsi hafi minnkað um tíu prósent á síðustu rúmlega tíu árum. Niðurstöður nýjustu rannsóknar alþjóðlegu samtakanna Blaðamenn án landamæra eru á svipuðum nótum. Á kjörskrá fyrir sveitarstjórnarkosningarnar á laugardaginn eru 302.688 manns. Það er kosið í 57 sveitarfélögum, kjörstaðir eru 129 og kjördeildirnar 293. Framkvæmdastjóri landskjörstjórnar skrifaði í grein á Vísi um helgina að ekki væri fjarri lagi að áætla að 1.400 til 1.500 manns yrðu að störfum í kjördeildum á laugardaginn. Og fjöldi þeirra sem komi með einum eða öðrum hætti að undirbúningi og framkvæmd kosninganna hlaupi á þúsundum og handtökin séu nánast óteljandi.
Episodio 113: Wing Commander: El bug que se convirtió en un "gracias". La historia del bug que se convirtió en cortesía. ¿Qué haces cuando tu código falla justo antes del lanzamiento y no tienes tiempo para arreglarlo? El equipo de Wing Commander (1990) nos dio la respuesta: ingeniería social. El problema: Un cierre accidentado El juego funcionaba de maravilla, pero tenía un fallo persistente: al salir al escritorio, el sistema DOS lanzaba un error de memoria muy feo. El equipo no encontraba el fallo y los discos tenían que irse a fábrica ya. La solución: El truco del editor hexadecimal El programador Ken Demarest decidió que, si no podía eliminar el error, lo escondería. Usó un editor hexadecimal para entrar en el código y cambió el texto del mensaje técnico "EMM386 Memory manager error. Bla bla bla" por: "Thank you for playing Wing Commander!" El resultado: Un éxito invisible Durante décadas, los jugadores pensaron que ese mensaje era un detalle de cortesía de los desarrolladores. Nadie sospechó que, en realidad, cada vez que leían ese "gracias", el juego acababa de sufrir un error de memoria. La lección: A veces, cuando la lógica falla, una buena gestión de la percepción del usuario puede salvar un lanzamiento millonario. Una "chapuza" genial que ya es historia de la informática.
Za provozní slepotu označuje přijetí miliardového daru v bitcoinech exministrem spravedlnosti Pavlem Blažkem (ODS) současný první místopředseda ODS Tomáš Portlík. I přes to, že Blažka před několika dny policie obvinila z legalizace výnosů z trestné činnosti a zneužití pravomoci úřední osoby, k vystoupení ze strany ho nevyzývá. Nakolik kauza poškozuje celou ODS, se ukáže v říjnových komunálních volbách, ve kterých bude Portlík usilovat o post pražského primátora. Kampaň už rozjel.
Happy Fishing Opener Weekend Listen Local Fam! On today's episode we catch up with someone who knows fishing very well, Nick Lindner. Nick, whose family is arguably the most recognized fishing family in Minnesota, talks about growing up a Lindner, if he always knew he'd be working in the fishing/angling industry, what it's been like branching off from typical TV media into growing his YouTube and other social media pages, and of course some tips and tricks as we head into Fishing Opener 2026. All of that, and much more from Nick! Then after Nick signs off, the LL Crew gives an update on the Pequot construction, a sports update, and other BLA news and events in the Local Happenings segment. As always, thanks to our amazing listeners and of course 2026 sponsors Pequot Lakes and Gull Lake Sanitation, Hanneken Insurance, Craguns Legacy Courses, Party Time Rental, Bens Marine and Motorsports and our PRESENTING SPONSOR Lakes Area CPAs! Instagram: ListenLocalMNBlazeAirProductionsWoodsToWaterMNNorthwoodsAgent Facebook:Listen Local MNBlazeAirMNWoodsToWaterMN
Three BLAs. Three companies. One industry-defining challenge.Jake Trees, Irving Ford, and Megan Callan on What It Really Takes to Cross the Commercial Line in Cell and Gene TherapyIn this special compiled episode of Let's Talk Quality, Hemish Ilangaratne brings together three quality leaders who have each led their organisation through one of the most demanding transitions in the industry: from clinical development to commercial manufacturing for a cell or gene therapy product.Jake Trees spent five years at Bristol Myers Squibb leading the quality function through the approval and launch of Abecma and Breyanzi, two of the first commercially approved CAR T cell therapies in the world. Irving Ford was the first quality hire at the Celgene cell therapy facility in New Jersey, built the QC organisation from nothing, and has since led quality through four BLA approvals across multiple cell therapy companies, most recently at Adaptimmune for the approval of Aucatzyl. Megan Callan is VP of Quality at Abeona Therapeutics, where she guided the quality team through the FDA approval of Zevaskyn, the first ever approved topical gene therapy for a rare genetic skin disorder.These are three distinct products, three distinct companies, and three distinct leadership journeys. But across all three conversations, the same themes surface: what it takes to build a quality team from scratch, how to shift the mindset of a clinical organisation towards commercial standards, and what the moment of approval actually feels like after years of sustained effort.In this episode, you will hear the following:Jake Trees on the setbacks on the road to BLA approval, including a refusal to file, cell growth failures during scale-up, and leading through a pandemic while hosting three health authority inspectionsIrving Ford on being the first quality hire at a new commercial cell therapy facility, building a team that grew to over 200 people, and why working in the gray is not a compromise but a core competency in this fieldMegan Callan on taking a quality team from five people to more than 60, coaching a clinical workforce into a commercial mindset, and what it means to empower people to make fast decisions when the patient is waitingThis episode is for anyone who is working towards a first commercial approval, scaling a quality function in cell or gene therapy, or trying to understand what it takes to lead through the most demanding regulatory and operational environment in modern pharma.Thank you to Jake, Irving, and Megan for sharing their journeys.Hope everyone enjoys the show.
En este podcast estrenamos "Alguien Ha Boicoteado El Ponche", nueva canción de La La Love You y una de las canciones que formarán parte de su nuevo disco, que ya tiene título, "¿Por qué me miráis así?" y fecha de publicación, 29 de Mayo. Escuchamos a sus amigos Monsieur Periné, desde Colombia con el disco que acaban de publicar, “Instrucciones Para Ser Feliz” y todo esto. RATA - De Mal en PeorARDE BOGOTÁ - Flores de VenganzaROYAL BLOOD - Where Are You NowNIÑA POLACA - Sería PerfectoMAXIMILIANO CALVO ft ÍÑIGO BREGEL - Es Una Ansiedad Tan CoolLOS ESTANQUES y ANNI B SWEET - Bla, Bla, BlaKNEECAP - Smugglers & ScholarsIDLES - DancerKERALA DUST - FeverMONSIEUR PERINÉ - Roncito con Coca (ft Luísa Sounza)BAD BUNNY - DfMFTRUENO, CALAMARO - 1000 HorasLA LA LOVE YOU - Alguien Ha Boicoteado El PoncheGINEBRAS - IntervenciónLEÓN BENAVENTE - Ayer SalíEscuchar audio
„Vždycky jsem se snažil jednat podle svého nejlepšího vědomí a svědomí, postupovat ve prospěch České republiky,“ říká bývalý premiér a někdejší dlouholetý předseda ODS Petr Fiala, který je dnes řadovým poslancem. Jak se srovnává s novou rolí? Jaké má v politice další ambice? Co říká na obvinění exministra Blažka v tzv. bitcoinové kauze? A jak hodnotí fungování ODS pod novým vedením? Poslechněte si rozhovor.
„Vždycky jsem se snažil jednat podle svého nejlepšího vědomí a svědomí, postupovat ve prospěch České republiky,“ říká bývalý premiér a někdejší dlouholetý předseda ODS Petr Fiala, který je dnes řadovým poslancem. Jak se srovnává s novou rolí? Jaké má v politice další ambice? Co říká na obvinění exministra Blažka v tzv. bitcoinové kauze? A jak hodnotí fungování ODS pod novým vedením? Poslechněte si rozhovor.Všechny díly podcastu Dvacet minut Radiožurnálu můžete pohodlně poslouchat v mobilní aplikaci mujRozhlas pro Android a iOS nebo na webu mujRozhlas.cz.
Výtah Respektu: Detektivové z Národní centrály proti organizovanému zločinu obvinili v takzvané bitcoinové kauze další tři lidi. Seznam Zprávy, Deník N a iRozhlas v pondělí odpoledne uvedly, že je mezi nimi i exministr spravedlnosti Pavel Blažek (dříve z ODS). Souvisí jeho obvinění s trestním oznámením, které podal současný ministr spravedlnosti Jeroným Tejc z ANO? Čeho se měl Blažek podle obvinění dopustit? Jak by mu jeho argumenty mohly pomoct, pokud se dostane k soudu? V úterní epizodě odpovídá Ondřej Kundra.
Vyšetřování policie v tzv. bitcoinové kauze, která loni zatřásla českou politikou, přineslo nově obvinění exministra spravedlnosti Pavla Blažka a dalších dvou osob. Podle detektivů se dopustili trestných činů, za které hrozí až mnohaleté vězení. Co se stalo, že případ právě teď dospěl ke zlomu? A kam může dál mířit?Host: Vojtěch Blažek - investigativní reportér Seznam Zpráv Článek a další informace najdete na webu Seznam ZprávySledujte nás na sociálních sítích X, Instagram, Threads nebo Bluesky. Náměty a připomínky nám můžete psát na e-mail zaminutusest@sz.cz
„Snažili jsme se pojmenovat ty věci objektivně. Koneckonců interní audit prováděli lidé, kteří tam byli ve stejných pozicích za pana exministra Blažka a za paní exministryně Decroix,“ říká o auditu, který předcházel trestnímu oznámení v bitcoinové kauze ministr spravedlnosti Jeroným Tejc (za ANO). Co ukázal jeden úspěšný a jeden neúspěšný pokus o útěk z českých věznic? A kam pokročilo ministerstvo spravedlnosti v úvahách o změnách trestního zákoníku? Poslechněte si rozhovor.
„Snažili jsme se pojmenovat ty věci objektivně. Koneckonců interní audit prováděli lidé, kteří tam byli ve stejných pozicích za pana exministra Blažka a za paní exministryně Decroix,“ říká o auditu, který předcházel trestnímu oznámení v bitcoinové kauze ministr spravedlnosti Jeroným Tejc (za ANO). Co ukázal jeden úspěšný a jeden neúspěšný pokus o útěk z českých věznic? A kam pokročilo ministerstvo spravedlnosti v úvahách o změnách trestního zákoníku? Poslechněte si rozhovor.Všechny díly podcastu Dvacet minut Radiožurnálu můžete pohodlně poslouchat v mobilní aplikaci mujRozhlas pro Android a iOS nebo na webu mujRozhlas.cz.
Jiří Svoboda, donedávna ředitel Správy železnic, kterého policie vyšetřuje kvůli podezřelým miliardovým zakázkám a u něhož našla v hotovosti 80 milionů korun, v době svého ředitelování velmi výhodně koupil byty v lukrativních pražských čtvrtích. Realitní firma při prodeji tratila několik milionů korun. Jak je to možné? A jak pokračuje vyšetřování původu peněz, které policisté našli při domovní prohlídce ve Svobodově bytě?Host: Vojtěch Blažek - investigativní reportér Seznam ZprávČlánek a další informace najdete na webu Seznam ZprávySledujte nás na sociálních sítích X, Instagram, Threads nebo Bluesky. Náměty a připomínky nám můžete psát na e-mail zaminutusest@sz.cz
Það hefur verið ófriðlegt í norðurhluta Nígeríu stærstan hluta aldarinnar, meðal annars vegna uppgangs hryðjuverkasamtakanna Boko Haram. Mannrán, morð og önnur ofbeldisverk hafa verið tíð. Eftir að dregið hafði úr ofbeldisverkum blossuðu þau upp aftur í fyrra, og nú er ástandið verra en nokkru sinni. Margir samverkandi þættir skýra ástæðuna, bæði samfélagslegir og efnahagslegir. Hallgrímur Indriðason fer yfir það. Læknar án landamæra eru meðal virtustu mannúðarsamtaka heims. Í rúma hálfa öld hafa starfsmenn þeirra lagt líf sitt að veði til þess að koma þeim allra hjálparlausustu meðal okkar til aðstoðar. Samtökin starfa á mörgum af hættulegustu stöðum í heimi og starfsmenn þeirra hraða sér gjarnan í áttina að hörmungum sem aðrir leggja á sig mikið að flýja. Þessi samtök, sem við heyrum svo oft minnst á í fréttum, eru þekkt fyrir að vera sumpart djarfari en önnur álíka mannúðarsamtök, og veigra sér ekki við því að storka yfirvöldum í þeim löndum sem þau starfa - á meðan önnur samtök starfa þar ekki nema með samþykki yfirvalda. Þessi djarfa nálgun hefur orðið öðrum innblástur og stofnuð hafa verið önnur samtök, með svipaða hugmyndafræði, eins og Blaðamenn án landamæra, Kennarar án landamæra, Lögfræðingar án landamæra og Verkfræðingar án landamæra, svo fáein séu nefnd. En hvernig er að starfa fyrir Lækna án landamæra og hvað er það, sem fær fólk til þess að stofna lífi sínu - síendurtekið - í hættu, til þess að hjálpa öðrum? Oddur Þórðarson ræðir við Íslending sem hefur gert nákvæmlega þetta í heil 10 ár.
Good day to all of our friends in the BLA! Let's get right into it. On today's show we have Dustin Smith from AutoSmith! From the early days of doing remote auto repair to now owning SIX locations all over the BLA, Crosby and McGregor areas the LL crew chat about it all. Among those many topics, Dustin dives into the struggles back in 07-08 when he began this journey, what made him stick with it, the importance of building a great team around him, some of the non-auto repair services that he and AutoSmith offer, and what he's learned as he approaches 20 years of service. Just an all around great Lakes Area small-business success story. Plus, what made him want to be the Presenting Sponsor of the Lakes Area Heroes Banquet. Huge thanks to Dustin for joining the show, and everything him and the AutoSmith crew do around the community! Then after Dustin signs off, the Listen Local crew dive into everything well... local in this week's Local Happenings Segment. And as always, thanks to our 2026 sponsors Pequot Lakes and Gull Lake Sanitation, Hanneken Insurance, Craguns Legacy Courses, Party Time Rental, Bens Marine and Motorsports and our PRESENTING SPONSOR Lakes Area CPAs! Instagram: ListenLocalMNBlazeAirProductionsWoodsToWaterMNNorthwoodsAgent Facebook:Listen Local MNBlazeAirMNWoodsToWaterMN
In this week's News Roundup, Bridget and Producer Mike cover the tech news stories you might have missed. TRIGGER WARNING - one story discusses disturbing sexual assaults. . Reese Witherspoon thinks women should embrace AI more. The comments were not kind. https://www.instagram.com/reel/DXKphAtkbgW/?utm_source=ig_web_copy_link&igsh=MzRlODBiNWFlZA== . Gisèle Pelicot's story of being drugged and raped by her husband and other men for a decade captured headlines. A new CNN investigation reveals a large ecosystem of men helping each other commit similar crimes around the world with something like an "online rape academy." https://www.cnn.com/interactive/2026/03/world/expose-rape-assault-online-vis-intl/index.html . Lauren Sanchez Besos is a cultural force, revolutionizing the way Americans live, and inspiring everyone with her embrace of joy and her perfect marriage to Jeff Bezos. Right? RIGHT?! (wrong) https://www.nytimes.com/2026/04/11/business/lauren-sanchez-bezos-jeff-bezos.html?unlocked_article_code=1.blA.i7qg.dQZ7G1_RUIcF&smid=url-share [gift link] Anti-Occupy Wall Street Champagne Toast Later Today? https://gothamist.com/news/anti-occupy-wall-street-champagne-toast-later-today Rich people watching Occupy protestor: https://www.threads.com/@yungbooks/post/DEEOKfUOXkA . Workers at surveillance company Flock inexplicably accessed cameras in a gymnasium and pool, prompting the city of Dunwoody, Georgia, to delay their contract renewal after a citizen's open records request revealed anomolies in the logs. https://www.theguardian.com/us-news/ng-interactive/2026/apr/06/flock-cameras-privacy-concerns . Why Are Flock Employees Watching Our Children? https://jasonhunyar.substack.com/p/why-are-flock-employees-watching-720 . Women in northern Nigeria have been writing steamy romance books for decades. They are fighting morality censorship by innovating new models of distribution and monetization on WhatsApp. https://www.nationalgeographic.com/photography/article/love-is-universal-but-nigerias-romance-lit-market-is-one-of-a-kind and https://www.nytimes.com/2026/04/09/world/africa/nigeria-erotica-writers-censors.html . Here are more stories we were watching this week: NAACP lawsuit accuses Elon Musk’s xAI of polluting Black neighborhoods near Memphis: https://www.theguardian.com/technology/2026/apr/14/naacp-lawsuit-elon-musk-xai-memphis A Redditor Criticized ICE. Trump Is Trying to Unmask Them by Dragging the Company to a Secret Grand Jury: https://theintercept.com/2026/04/10/reddit-ice-protest-grand-jury/ What is dynamic pricing at grocery stores? Maryland now bans it: https://www.usatoday.com/story/news/2026/04/15/maryland-bans-dynamic-pricing-practice-popular-among-retailers/89621751007/ Meta’s new rules let it ban users or suppress comments that include the word “antifa” alongside “content-level threat signals.” https://theintercept.com/2026/04/14/facebook-instagram-antifa-censor/ Let us know what you think by emailing hello@tangoti.com or leaving a comment on Spotify. Pre-order Bridget's forthcoming audiobook about AI and intimate relationships at LoveAtFirstPrompt.com ! Follow Bridget and TANGOTI on social media! || instagram.com/bridgetmarieindc/ || tiktok.com/@bridgetmarieindc || youtube.com/@ThereAreNoGirlsOnTheInternet || bsky.app/profile/tangoti.bsky.socialSee omnystudio.com/listener for privacy information.
00:00 – laimėkite žaidimų kompiuterį 07:25 – mirė R.Cvirka 09:23 – M.Blaževičiaus sugrįžimas 16:01 – R.Milašiaus pasisakymai 25:55 – kas nutiko Kėdainiuose 35:22 – teisėjų paskyrimas 37:10 – J.Mačiulio darbas „Lietkabelyje“ 41:29 – NCAA iškreipia rinką 48:51 – kodėl savivaldybės tiek skiria paramos klubams 52:08 – viena pavojingiausių darboviečių ir mūsų tobulėjimas 57:06 – E.Stenionio žaidimas 59:20 – ar „Lietkabelis“ ims bronzą 1:05:20 – žaidėjo susitarimo sulaužymas 1:08:18 – Ch.Moneke išdavė S.Francisco ateitį? 1:10:30 – J.Robinsonas ar M.Morganas 1:14:07 – ketvirtfinalio varžovas
Norėdami matyti visą podkastą spauskite čia: https://contribee.com/krepsinisnet 00:00 – išvyka į Prahą 04:10 – trenerių atleidimai 10:30 – „Žalgirio“ pergalė Belgrade 22:59 – kas bus varžovas? 33:20 – teisėjai išsprendė rungtynes Utenoje 43:49 – „Neptūnas“ klupo prieš „Nevėžį“ 49:15 – „Ryto“ pagirios 57:41 – „Lietkabelis“ laimėjo užtikrintai 1:02:25 – M.Buzelis laukiamas rinktinėje Rėmėjų dalyje aptartos šios temos: 1:08:35 – N.Williamso-Gosso išpildytas lūkestis 1:13:53 – paskutinis sezonas D.Giedraičiui? 1:17:31 – ką darys M.Rubštavičius ir I.Sargiūno klausimas 1:26:15 – ekipą paliksiantis D.Sirvydis ir M.Grigonis 1:31:50 – du blogiausi kainos–kokybės kontraktai 1:36:20 – vietoje S.Francisco – du žaidėjai? 1:44:35 – A.Butkevičius ir E.Ulanovas 1:47:35 – pakels algą T.Masiuliui ir didesni pinigai D.Slevai 1:51:10 – trys centai su M.Blaževičiumi
Deb (00:03.606)Within the next seven months, up to 1.5 million Americans could lose access to a medication that they’ve relied on for decades. Not because it’s dangerous, but because a pharmaceutical giant may have lobbied the FDA to eliminate their competition. And if you’re one of them, your doctor may already have told you about this issue and stopped prescribing it.This isn’t a conspiracy theory. This is documented in federal court filings. This is happening right now. And the company that stands to profit, well, they’re the same ones manufacturing the only product that might survive.Today on Let’s Talk Wellness Now, we’re exposing the desiccated thyroid extract crisis, the corporate manipulation behind it, and what you need to do right now to protect your health. Stay with me because I’m about to share what could save your access to the medication keeping you alive.Welcome back to Let’s Talk Wellness Now, the show where we uncover the root causes of chronic illness, expose regulatory capture in healthcare, and empower you with the tools to advocate for yourself. I’m Dr. Deb, naturopathic doctor, your medical detective, and today we’re diving into one of the most consequential and corrupt healthcare decisions affecting patients right now. If you or someone you love takes Armour thyroid, NP thyroid, or any desiccated thyroid extract,for hypothyroidism or if you’ve struggled to find a thyroid medication that actually works for your body, this episode is absolutely critical. And if you have celiac disease, gluten sensitivity or corn allergies, what I’m about to reveal will make your blood boil. Now grab your cup of coffee, don’t forget your notebook and settle in because what’s happening to this medication right now is a masterclass in how pharmaceutical companies use regular Deb (02:06.544)agencies to eliminate competition, control markets, and price gouge patients. And I have all the receipts. Deb (02:20.982)Let me start with what might surprise you. Desiccated thyroid extract, or DTE as we call it, is actually one of the most oldest thyroid medications in the world. And I mean old. From the 1890s through 1970, this was the standard treatment for hypothyroidism.Now let’s really dive into that. From the 1890s to the 1970s, this was standard hypothyroidism treatment.In 1965 alone, and this is documented in peer-reviewed literature published in the Journal of Clinical Endocrinology and Metabolism, approximately four out of every five prescriptions for thyroid hormone in the United States were of natural desiccated thyroid preparations.The Journal of Clinical Endocrinology and Metabolism is a very high-end journal. Now think about that. This wasn’t some fringe therapy. This was mainstream medicine. Armour Thyroid, the most recognizable brand name, has been manufactured since the early 1900s, well over a century ago.and this is cited again in NIH bookshelf. When the FDA was officially established in 1938, Arbor thyroid was already on the market. And this is important and I want you to understand why. Under the federal Food, Drug and Cosmetic Act, any drug that was already being marketed before 1938 was automatically grandfathered into the system. That means it didn’t have to Deb (04:08.112)go through the formal FDA approval process. And this again is cited under the Federal Food, Drug and Cosmetic Act, grandfathered drugs and exemptions. And this is crucial to understanding what happens next. By the 1970s, synthetic levothyroxine, brand name Synthroid and generics became the preferred treatment. Hmm, wonder why?It was easier to standardize, came into consistent doses, and worked well for most patients, and could be mass manufactured. By the 1980s, levothyroxine had largely replaced desiccated thyroid in clinical practice, according to the American Thyroid Association 2014 guidelines for the treatment of hypothyroidism. But here’s what matters. Some patients…a very significant minority of them, never felt right on levothyroxine alone. Despite their lab work looking normal, they still had fatigue, brain fog, weight gain, cold intolerance, and depression.These patients often found relief when they switched back to their desiccated thyroid, which contains both T4 and T3 hormones, the way human thyroid naturally produces them. And this is not anecdotal. This is documented in randomized double-blind crossover studies published in Endocrine Practice.For decades, that was fine. Their doctors prescribed it, insurance sometimes covered it, patients were getting better, and the system worked really well. Until August 6th of 2025, just a short time ago, everything changed. On that date, the FDA sent letters to manufacturers, importers, and distributors of desiccated thyroid extract products stating that these medications would need an approval. Deb (06:04.654)a biologics licensed application, a BLA, to remain legally on the market. And this is cited in the FDA’s official statement, FDA’s actions to address unapproved thyroid medications. understand it says unapproved thyroid medications. However, desiccated thyroid, specifically Armour, has been approved since 1938. And this was dated August 6th through 7th, 2025.This wasn’t a guideline. This wasn’t a suggestion. It was an endorsement of action. And the timeline they gave them? Well, just 12 months to transition patients to another medication before enforcement action could begin.This was also cited by an FDA notice to the industry, animal derived thyroid products notice to industry, August 6th, 2025. Now do the math, that means August 2026, seven months from now, 1.5 million Americans currently taking this medication. And this number comes from the FDA official statement, citing that it’s an estimation of 1.5 million patients receiving prescriptions for these medications.could potentially lose their thyroid access. Now, here’s where it gets interesting. The FDA didn’t wake up in August of 2025 and decide to regulate desiccated thyroid after a century. This decision has a much longer backstory. And understanding that backstory is critical to understanding what’s really happening in this industry.The shift started in 2022. Back in September of 2022, over three years ago, an FDA branch chief sent a letter to the National Associations of Boards of Pharmacy noting that the agency had decided to designate DTE as a biological product, which would affect its eligibility for compounding. Deb (08:13.972)This also is cited in an FDA letter to the National Association of Boards of Pharmacy September 2022.Then two months later, in November of 2022, the FDA’s Office of Compounding Quality and Compliance sent a softer letter acknowledging that many Americans take medication to treat hypothyroidism and some choose to take DTE products. The letter stated that the FDA would focus enforcement on cases that pose the greatest public health risks, such as serious adverse offense or serious product quality or adulteration.also is cited by an FDA letter from Francis G. Bromel, the director, Office of Compounding Quality and Compliance, November of 2022. Now, let me just think about this for a second. If this drug has been on the market since the 1800s, been FDA approved since 1938, would we not have seen a health crisis long before 2022?I honestly don’t know of any other drug that’s been around this long that’s used by this many people. Now granted, I haven’t done the research on it either, which I can do for you guys, but I’m just thinking if a drug is on the market today and it causes harm, it doesn’t make it three years, five years before you see lawsuits everywhere. Why are there no lawsuits on this drug? Why are there no major reactions that people are seen having?Hmm, just thought. But here’s the pattern. The FDA was already laying the groundwork back in 2022, testing the waters, signaling where this was headed. The August 2025 action. Then this came down. Deb (10:09.806)August 6, 2025, the FDA announced its position publicly and sent formal letters to all DTE manufacturers, importers, and distributors. This was cited by the FDA Enforcement Action August 6, 2025, letters to manufacturers, importers, distributions of DTE products. The agency stated several concerns. First, DTE products have experienced quality and dosing issues.The FDA cited, and I’m quoting directly from their statement, over 500 adverse events reported associated with DTE products from 1968 to 2025. From 1968 to 2025, we had 500 adverse reactions? What is that math equate to?A couple a year? Come on guys, this is insane! With a substantial increase, you, between 2019 and 2020 that the agency suggested was related to voluntary recalls of sub-potent or super-potent products.This was cited in the FDA statement, over 500 adverse events reported associated with ADT products from 1968 through 2025.Second, the agency expressed concern about batch inconsistency. According to the FDA’s official statements, tablets made from the same manufacturing batches may not always provide the same thyroid hormone levels. Okay, this was cited in the FDA statement, tablets made from the same manufacturing batches may not always provide the same thyroid hormone levels. Thirdly, and I want to actually let’s back up. I want you to remember I said that Deb (12:11.216)because further down in this podcast, we’re going to talk about this. This is an important point to remember. Thirdly, the agency raised concerns about potential impurities from animal source material, including potential for viral contamination due to the animal source and supraphysiological levels of T3.the FDA statement on impurities, viral contamination and super physiological T3 levels. Now I will tell you, I’ve been prescribing armarithograde for 20 years. I’ve rarely seen a super physiological dose given of T3 in lab results, unless the patient takes their medication like four or five hours before you do the blood test, then you’ll see a false rise because you’re actually seeing the medication. You’re not seeing people walking aroundsuperphysiological T3 levels. Nobody would like that feeling. So anyway, I digress. Now let me pause here because this is where I need to give you some context that the FDA hasn’t quite emphasized yet. Of course, we have another connection and it is the China connection.So the FDA’s concerns about contaminated drugs and quality issues don’t exist in a vacuum. In 2024, the U.S. over 828,000 metric tons of pharmaceuticals, seven times the level from 2000. And here’s the kicker. China and India supply the majority of active pharmaceutical ingredients. APIs for U.S. generics accounting for 70 to 80 % of the total genericdrug supply. According to Reuters industry report in 2024, they state that China supplies 82 % of the APIs for critical drugs. Deb (14:08.204)Got to question that, right? Why are we giving all of our drug formulas to China and allowing them to import them into our country? In fact, roughly 20 % of the critical drugs have APIs exclusively sourced from China. And China controls 80 to 90 % of the global production for antibiotics and other key compounds. This was also cited by Reuters industry data thatcontrols 80 to 90 percent of the global production for antibiotics and other key compounds. Now just think about this. They control 80 to 90 percent of our medication. They control 20 percent of our critical drugs and we just put what kind of tariff on them? Hmm.In 2025 alone, the FDA issued multiple warning letters to foreign manufacturers for contamination issues and failure to follow good manufacturing practices. This is also cited by the FDA warning letters 2024 through 2025 and multiple citations to foreign manufacturing facilities. This is a systematic problem affecting the entire US drug supply, not just desiccated thyroid.So when the FDA suddenly became concerned about DTE quality and contamination, part of that concern was legitimate. But this is crucial. The same inconsistencies and contamination issues exist across the entire generic drug supply. And the FDA has not taken the same enforcement action against them. Let that sink in.They have not taken the same enforcement action against the other drug companies. So what’s behind all of this? Where is this all coming from? Hmm. Let’s address something directly, because you deserve to know it. And I’m going to cite my sources precisely so that when the medical boards have something to say about this, and they might, I have a documentation for every single word that I am about to speak. Deb (16:24.878)According to the court documents filed in October 2025, in the case ofa urine, a urine. I’m going to say that wrong. Pharmaceuticals versus Dr. George Tidmarsh from ABBV, the multinational pharmaceutical company that manufactures armor thyroid, reportedly petitioned the FDA in 2024, asking the agency to reclassify DTE as a biologic and to prohibit other manufacturers from selling unlicensed DTE products unless they havehad an investigational new drug application, we call this an IND, and a clinical development program aimed at eventual approval. This is cited in the court filing a Urena pharmaceuticals lawsuit versus Dr. George Tidmarsh, October 2025, reported by Fierce Pharma. Now let me explain why this matters and why this is one of the most brazen examples of regulatory capture I’ve ever seen in my career.AbbeVee is one of the world’s largest pharmaceutical companies. In 2024, they reported over $54 billion in revenue. Drop the mic on that one.They have the resources, the regulatory expertise, the legal teams, and the financial capacity to navigate a biologics license application process that costs between $500 million and $1 billion. Let that sink in. Deb (18:07.882)A drug that’s been on the market since the 1800s that was grandfathered in 1938 that’s making plenty of money right now. They’re going to spend 500 million to $1 billion to get a biologics license application. Why would they do that? Well, we’re about to find out. Most otherDTE manufacturers, smaller companies like Acela Pharmaceuticals, which makes NP-thyroid, and RLC Labs, which made WP-thyroid, do not have those same resources. And this is cited in Pharma Voice in 2025. Why a treatment older than the FDA is getting new regulatory scrutiny. So when you petition the FDA to reclassify a drug in a way that requires this type of expensivetime-consuming biological approval, you’re not just asking for safety. You’re asking to eliminate your competitors from the marketplace. Now, I want to be very precise here. These allegations are documented in federal court filings, and it hasn’t been approved in court. It’s also been reported by multiple industry sources, including Fierce Pharma. But I’m telling you,what has been reported in legal proceedings, not stating it as an absolute fact because you deserve to know the difference and because I have to protect my license. Now, what do we know for certain?AbbeVee is working on a biologics license application for Armour thyroid through clinical trials called Avantia. This is cited by the AbbeVee corporate statement 2025 Avantia clinical trial for Armour thyroid. A cell of pharmaceuticals has been pursuing BLA approval for NP thyroid for seven years since 2017 and it completed its phase two trials successfully in 2025. They’re now moving Deb (20:15.448)into Phase 3 trials. This is also cited by the Acela Pharmaceuticals CEO statement 2025 seven-year pursuit for BLA approval completed Phase 2 trials moving to Phase 3.RLC Labs, which manufactured WP thyroid, has made no public announcement about pursuing BLA approval and really probably don’t have a plan to do this since they’ve been off the market for some time now. About five years, I think maybe a little longer. Here’s the market manipulation.If only ABBV is successful and obtains a BLA approval for Armour thyroid, that company would effectively have a monopoly on the DDT market. And in pharmaceutical markets, monopolies historically lead to price increases.We’ve seen this pattern over and over again when turning pharmaceuticals acquired Daraprim and raised their price from $13.50 to $750 per tablet overnight. When Myelin raised EpiPen increased prices by 400 % when insulin manufacturers colluded to raise prices in lockstep. This is the playbook.use regulatory barriers to eliminate your competition and then exploit pricing power. For a drug that’s been on the market since the 1800s, guess corporate greed is everywhere. They’re not making enough money on this product already and they’re taking advantage of the rules that they can manipulate their competition by. And here’s what really makes me furious. The American Thyroid Association, the professional organization Deb (22:06.672)representing endocrinologists sent letters to the FDA commissioner on October 8th of 2025 and September 18th of 2025.advocating for continued patient access to DTEs. This is cited in the American Thyroid Association statement and letter to the FDA commissioner dated October 8th, 2025 and September 18th, 2025. The American Association of Clinical Endocrinologists issued a statement on September 9th of 2025 supporting equitable access and personalized medicine for DTE. This was also cited in the American AssociationAssociation of Clinical Endocrinologists, AACE, statement dated September 9th, 2025. Even the medical establishment, which has historically favored levothyroxine, is saying, wait, this is going too far. Patients need access to this medication. But the FDA is moving forward anyway. Why? Well, where does it always lead us? Follow the money trail.Okay, so I need to explain what a biologics license application actually is because this is where the rubber meets the road for what’s going to happen to pricing and availability. What is a BLA?A BLA is a biologics license application. It’s a formal request submitted to the FDA to market a biologic product in the United States. A biologic is defined under the Public Health Service Act section 351 as a product derived from or made using living material, in this case, animal thyroid glands. And this is cited in the FDA definition for biologic products. So they’re putting armor thyroid right Deb (23:57.377)right up with stem cells and exosomes. Think about that. Stem cells and exosomes cost thousands of dollars per application because of how they have to be harvested, stored, freezed, all of that. But we’re talking about a thyroid gland. Good Lord, people.Unlike regular drug applications for synthetic medications which follow a simpler pathway, the BLA process is designed for complex biological products like monoclonal antibodies, vaccines, and gene therapy products. It’s a much more expensive, much more time-consuming process. The BLA processis what manufacturers have to do. And we’re going to talk about that. So according to Reprocell and Forge Biologics analysis of the FDA’s BLA process, here’s what companies need to submit. First, they need to complete a clinical trial data, phase one, two, and three trials, proving safety and efficacy for desiccated thyroid. Haven’t we done that since it’s been on the market since the 1800s? Just saying.This means they have to conduct large randomized controlled trials comparing it to levothyroxine, measuring safety outcomes, efficacy outcomes, and quality of life metrics. Second,Chemistry, Manufacturing and Controls, CMC’s data. Detailed information about how the product is manufactured, quality control measures, stability testing and specifications that must be met for every batch. Third, preclinical and animal safety data. Fourth, labeling and product information. Now, I think we have labeling and product information. Deb (25:53.717)since the 1800s? But just saying. Fifth, they need Pharma Covigilance Plan, a detailed plan for monitoring safety after the product is on the market. Haven’t they had to do that since the 1800s? And they have to have a timeline. And this is the critical part. The FDA’s standard review time for a BLA is 10 months.That’s after the application is deemed complete and accepted for filing. So this is cited by the FDA standard review timeline, BLA submission, and FDA review.Now, before you even get to filing, you need to conduct the clinical trials and compile all the data that’s typically several years of work. How are you going to prove safety and effectiveness in a large clinical trial long term? What do they consider? What do they deem long term? Three months, six months, a year, two years. These companies had 10 months.Well, maybe 12. They did it a year in advance. But unless you knew this was coming, how are you going to put together a trial, enroll the people, have all the trial components set up and ready to go in less than 12 months unless you knew it was coming beforehand? Even ifhad started all their clinical trials in 2024, completing them, compiling the data, and getting a complete application ready for submission, this would likely take you through mid-2026, then add another 10 months for FDA review. We’re looking at 2027 at the earliest for most of these companies to receive a BLA application. Deb (27:54.319)But the FDA gave the manufacturers until August of 2026. That’s approximately 19 months from when the August 2025 letters were sent. Most companies cannot reasonably complete the BLA approval in that timeframe. And when I’m talking about the 19 months, I’m talking about the information they would have had earlier. Now the cost.This gets me even more frustrated. Why are we spending this kind of money? The BLL process is extraordinarily expensive. The current FDA user fee for a BLA submission is approximately $483,560 just for the filing fee. And this is cited at the FDA user fees prescription drug user fee rates for 2025.The full cost of conducting clinical trials, CMC studies, and all the supporting documentation typically ranges from $500 million to over $1 billion, depending on the scope of the trials and the complexity. And this is cited in JAMA’s network, Open2023. A cell of pharmaceuticals has been pursuing the BLA approval since 2017. That’s eight years. And it’s just now.moving into phase three trials with a planned enrollment of approximately 300 patients. This is cited by the Acela Pharmacies CEO statement of 2025. Now that’s unusual. That’s typical for this process. This is not unusual. This is typical for this process to take seven, 10 years to get approval for this. So if Abby’s the one that requested this,Abby V. And Acela started this in 2017. Was Abby V threatened by Acela that Acela might get this approval and it would be quietly done without anybody seeing it? And maybe Abby V would be left out of the market after a century? Who knows? It’s possible. Deb (30:13.112)But for smaller manufacturers without billions in revenue, this cost is completely prohibitive. And this is why this matters. When you push an old established medication through an extraordinary, expensive approval process with a compromised timeline, one of three things happen. First, only the largest companies can afford it, creating a monopoly. And when that happens, the company that holds the only approved product can set pricing withminimal competitive pressures. Two, smaller manufacturers can’t afford it and their products disappear and the market shrinks and access decreases. Three, we see a combination of both and who pays the price? Literally, patients do. Now here’s whereThere’s something I want you to really think about because this is where the regulatory argument falls apart when you look at it carefully. The FDA’s concern about DTE is that, and I’m quoting their official statement, tablets from the same manufacturing batches may not always provide the same thyroid hormone levels. This is from their FDA statement.And that’s a legitimate quality concern, right? It is. Thyroid medications have a narrow therapeutic window like any other hormone, meaning the difference between an effective dose and the dose that causes problems can be quite small. But here’s what the FDA doesn’t emphasize. Generic drugs have the exact same dosing inconsistency issue, and it’s considered acceptable and has been since we allowed generics on the market.So how does a generic drug dose work anyway? Well, for generic drugs to be approved as bioequivalent to a brand name medication, the FDA requires that the generic drugs bioavailability fall within 80 to 125 % of the brand name product. Isn’t that a dose inconsistency? Deb (32:22.894)from the brand name medication? 800 or sorry, 80 to 125%. According to the pharmacy times analysis of the FDA’s bioequivalent standards, the 80 to 125 % bioequivalence rule means that a generic drug can have 20 to 45 % variability compared to the original brand product.Now, most generics are much closer than that. The FDA study data shows that the mean difference for an AUC value between generic and reference products is about three and a half percent in the two year post-Waxman hatch period, and 80 % of the generics fall within a five percent range. But the FDA’s regulations allow for that much higher variability. And this is cited in an FDA study data mean difference for AUC.Now, let me put this in plain language. A patient could take a generic levothyroxine tablet where one batch provides, say, 75 micrograms of an active thyroid hormone. And the next batch from a different manufacturer, a different generic manufacturer, could provide up to 93.75 micrograms, 125 % of that 75. That’s an 18 microgram difference.in the same prescribed dose. Now, this is considered acceptable and patients tolerate it and this system works.Yet the FDA’s argument against DTE is that batch-to-batch inconsistency is unacceptable and requires this expensive biologic approval? That’s a double standard. So why is batch inconsistency acceptable for generic levothyroxine, but supposedly unacceptable for desiccated thyroid? I’ll give you the regulatory answer. Deb (34:29.366)because DDT is a biological product derived from an animal tissue and the FDA considers biological products to require more rigorous control. That’s the regulatory answer, but I’ll give you the real answer.because there’s no billion dollar pharmaceutical company with a patent pending on generic levothyroxine who petitioned the FDA to regulate their competitors more strictly. The inconsistency argument is legitimate, but it’s selectively applied. And that matters when you’re trying to understand whether this is really about patient safety or whether it’s about market control.Now I want to talk about something that hasn’t gotten nearly enough attention in this discussion and it’s something that makes me absolutely furious. What is Armour Thyroid? According to the official prescribing information published by AbbeV and available through rxabbev.com and the FDA’s daily med database, Armour Thyroid contains the following inactive ingredients. Calcium steroid,dextrose derived from corn, mycocrystalline cellulose,sodium starch glycolate and a opadri white coating. Now let’s talk about dextrose. Dextrose is a sugar derived from corn and while manufacturers claim that the corn derived dextrose in armor thyroid is gluten free, here’s the problem. Cross contamination during corn processing can introduce gluten proteins especially if the corn is processed in facilities that also handle Deb (36:18.808)wheat, barley, or rye. Corn sensitivity is extremely common in patients with celiac disease and non-celiac gluten sensitivity, and studies show that up to 50 % of the celiac patients react to corn proteins due to molecular mimicry, and the corn proteins look similar enough to gluten that the immune system attacks them. And this is cited by RestartMD.com.And here’s what’s documented in peer-reviewed medical literature in a 2023 case report published in Case Reports in Endocrinology. These researchers documented five patients with gluten intolerance or celiac who were taking natural desiccated thyroid. Three of those patients also reported lactose intolerance. Now these patients had to switch from DTE to liquid levothyroxine formulations to avoid the inactiveSo here’s my question. If AbbeV becomes the only manufacturer with an approved DTE product and their formulations contain corn-derived dextrose that triggers reactions in celiac patients, what are those patients supposed to do? They can’t take armor because of the corn. They can’t take compounded DTE because the FDA is banning compounding of these biologics. They can’t take NPKsor WP thyroid because those companies may not survive the BLA process. So they’re left with a synthetic version of levothyroxine which may not work for them.Now the NP thyroid and WP thyroid difference. Now here’s what’s interesting according to drugs.com comparison of inactive ingredients and P thyroid and P thyroid has calcium steroid dextrose also derived from corn, mineral oil, multi-crystalline cellulose. Deb (38:19.31)cross carmelicin sodium and a opadri to white. So NP thyroid also has corn-derived dextrose. WP thyroid on the other hand was specifically formulated to be hypoallergenic according to ROC labs, but it’s no longer available and its ingredients were inulin from chicory root and medium chain triglycerides. No corn, no gluten, no common allergies. So todayWe do not have a glandular thyroid, a DTE, that is not potentially contaminated with gluten. Yet, patients with autoimmune thyroid disease are supposed to avoid gluten.Now, some of these people can handle a DTE and many cannot, so that argument could be a mute point. But at the end of the day, the one product that we had that was designated for patients with multiple chemical sensitivities, celiac disease and coron allergies, has been off the market for a long time already.We have a monopoly problem. So if ABBV becomes the only approved manufacturer, patients with these celiac diseases and corn allergies will either be forced to take a medicine that makes them sick and triggers their immune reaction or switch to a synthetic that doesn’t adequately treat their hypothyroidism or choose to go without treatment. This is not hypothetical. This is real patients with real medical needs who are about to lose accessto the only formulation that works for their body. And the FDA’s response is silence. Deb (40:07.69)Now I want to highlight something that hasn’t gotten nearly enough attention in this discussion. Compounding pharmacies. What is a compounding pharmacy? Compounded medications are custom made by licensed pharmacists to meet a patient’s specific needs. Maybe you need a different strength that was commercially available, but you have an allergy to a filler or a dye in the commercial product. Maybe you need a liquid formulation or instead of a tablet or you need a capsule. That’s when compoundingin. And the FDA’s, this is the FDA’s definition of compounding. And for decades, compounding pharmacies have been making desiccated thyroid extract for patients who needed customization. Some patients couldn’t take the commercial products because of the dyes and the fillers, and some needed strengths that were not available. And these compounding pharmacies filled the gap.But reclassification changes everything. When the FDA reclassified DTE as a biologic in 2022 and reinforced that decision in August of 2025, explicitly stated, and I’m quoting directly from the FDA’s official statement, these unapproved animal-derived thyroid medications are not eligible for compounding because these products are regulated as biologic products under the Public Health Service Act.How can that be? These products have been approved since 1938 and the Biologics Act didn’t go into effect or doesn’t go into effect until August of 2026.So how in 2022 were they able to say that the compounding pharmacies could not make these products? Anyway, what this means is after August 2026, compounding pharmacies will no longer be permitted to compound a desiccated thyroid extract, even for patients with specific medical needs. Now, compounding pharmacies can still compound T4 and T3 separately, synthetic versions of levothyroxine and liothyronine, according to Deb (42:12.728)healing dose compounding pharmacy. These pharmacists can create custom ratios of these two synthetic hormones to approximate what a patient was receiving from a DTE. But that’s not the same thing. Some patients respond better to the whole DTE preparation than to a compounded synthetic combination. And for patients with specific allergies to standard fillers like your celiac patients that I just talked about, losing the ability to get a compounded DTE alternative isreal hardship. This is going to be a ripple effect. For a subset of patients, maybe 5 to 10 percent of those on DTE compounding was their lifeline and it was their way to get a medication formulation that worked for their unique body. When compounding goes away, these patients lose that option as well and for some it will be a significant problem. Now let’s talk about what this likely means for your wallet.The current pricing right now, according to SingleCare and GoodRx, Armour Thyroid costs approximately $150 to $157 for a 90-day supply of 60-milligram tablets, about $1.67 per tablet. With discount cards, some patients can get it down to $101 to $152 for a 90-day supply.Generic levon thyroxine costs about $70 for a 90 day supply, less than half that price. And p-thyroid costs approximately $133 for a 90 day supply of 60 milligrams with a discount card about $83 to $101.What happens after we get BLA approval? Well, here’s the pharmaceuticals pricing model. When a company spends 500 million to $1 billion to bring a product to market, including conducting massive clinical trials, the cost tens of millions of dollars they recoup in that investment through pricing power. And this is cited in the pharmaceutical pricing models. If ABBIEV is the only company with an approved BLA of DTE, Deb (44:18.248)They have pricing power. They don’t have competitors. They can set their price, whatever they want. And historically, when drugs transition from grandfather status, which is basically unregulated to formal formally approved status, prices often increase significantly, not always, but often. And typically they have to get re-approval for insurance. SoTouring Pharmaceuticals acquired DARPM and raised the price again from $1,350 to $750 overnight, a 5,000 % increase. This is the playbook.Let’s talk about insurance coverage. This is the other consideration. Insurance companies sometimes have different coverage policies for approved versions versus unapproved drugs. And right now, many insurance plans cover armor thyroid or NP thyroid, even though they’re technically unapproved because they’ve been on the market for decades and patients are on them. Once a drug becomes formally approved, insurance companies may have new contractual relationships, prior authorization requirements, or preferred drugs.list that could affect your coverage. If 1.5 million people have to get a prior auth for their insurance to cover this new medication, this is going to drive the doctor’s offices crazy. We do not have the staff to man this. We do not have the manpower. We do not have the time. This is going to interrupt people’s ability to get their medications. This is going to create chaos within the system. And some patients might see better coverage, but manymost likely are going to see worse coverage and some might find themselves in a situation where they need to try to get the drug approved first or get an approval for something else like levothyroxine and they’re going to have to document that it didn’t work and the documentation that they had from 20 years ago is probably not going to be enough because it’s not documented anywhere. It’s lost in the system after 10 years. So for patients the practical takeaway is expect Deb (46:25.774)a price increase. I would say possible, but I don’t think that’s true. think you’re going to see a price increase if they get approved. Expect possible insurance complexities, budget accordingly, talk to your insurance company now about what your coverage is going to look like in 2027 if they even know. And if you want my honest assessment of what is likely to happen,I’ll give you a scenario, 30 % likelihood. The FDA enforces the August 26 deadline and DTE products not approved by then are pulled from the market. Patients will have 30 to 90 days to transition to other medications. Some patients suffer significant symptom relapse. Compounding for DTE becomes illegal and this disruptiveness of the system creates a real hardship. Scenario two.which is 50 % likely. This is actually what the FDA commissioner, Marty McCreary suggested on August 13th of 2025 when he posted on social media. The FDA is committed to pursuing the first ever approval of desiccated thyroid access pending results of the ongoing clinical trials. In the meantime, we’ll ensure access for all Americans. Hopefully that continues. What this likely means is the FDA uses enforcement discretion to allow continuedsales while approvals are being pursued and the deadline gets extended. Maybe patients get access for another two to three years while companies work on a BLA approval. This would be the least disruptive scenario, but it’s also legally uncertain because the enforcement letters have been formally rescinded. And scenario three, which is 20 % likelihood, one or two companies get BLA approval. Those products stay on the market at higher product prices and companies, products, other companiescompanies, products are pulled, the market shrinks, availability is limited, prices are higher, but patients can still get something. This is likely if a seller successfully completes phase three trials for NP-thyroid. And my assessment is based on the regulatory language and the enforcement letters that have not been rescinded yet, that the pattern of FDA enforcement, I believe scenario two enforcement discretion with an extended time frame is most likely what we’re going to see. Deb (48:49.488)doesn’t mean patients should sit back and do nothing. It means you should be prepared for change while advocating for access. If you want to keep Arm or Thigh Right on the market, 1.5 million people need to start talking about this publicly and flooding our Congress people, Bobby Kennedy, the FDA, with what you want to see happen. We have the ability to shape this and to change this with our voice. But if we sit back on our laurels and we do absolutelynothing. What is going to happen is what the FDA wants to have happen and ABV wants to have happen because they’re going to simply think people don’t give a shit. And if the American people are going to be lazy and not want to step forward and actually start using their voice for some good and instead of just going to social media and bitching and hoping something is going to happen, well, then we’re going to get what we deserve. But if you start taking someaction and you start advocating for the things that you want. Contacting your representatives, contacting your U.S. tell them the FDA has done this. Many of them may not know this, may not be on their radar. Tell them what you want. Start going after this. Start writing to the FDA Commissioner’s Office. They have a website. They have a Commissioner’s Office at fda.hhs.gov. Be responsible.respectful, but be firm. Explain your scenario. How long you’ve been on DTE. Why levothyroxine doesn’t work. What symptoms you experience when not adequately treated. How this decision will affect your quality of life and your pocketbook. Let’s do something proactive. So let’s consider this. Moving forward, work with your provider who understands the regulatory landscape around DTE. You can discuss the evidence for and against combination therapy.You can monitor for thyroid function with free T3 and free T4 testing, not just TSH. If you’re willing to try individualized approaches, you can do that. If you need help finding a functional medicine provider who understands this issue, come to serenityhealthcarecenter.com or explorethevanari.com. It’s a self-directed functional medicine support group. And right now what is happening is going to shape how history Deb (51:19.024)is made with not just armor thyroid, but many drugs to come. And it is important for you to take action. So I want to thank you for joining me today on Let’s Talk Wellness Now. This episode is about far more than thyroid medication. It’s about your right to personalized medical treatment. It’s about your regulatory capture and corporate influence. And it’s about what happens when billion dollar companies shape healthcare policy in ways that reduce patient choice and increase their profits.this episode resonates with you or you know somebody who’s going to be affected by desiccated thyroid, please share it. Post it on social media, send it to your doctor, email it to your representatives, tag AbbeVee, tag FDA. Make noise because the only way we stop this is if we make it too politically costly for them to continue. Your voice truly matters. Your health truly matters and you deserve access to treatments that work best for your unique body.If you’re ready to explore comprehensive personalized health care that puts you in control, visit us at SerenityHealthCareCenter.com. Learn more about functional medicine approaches to thyroid and beyond and explore my new platform, Venari.com, which is a self-directed functional medicine tool. Thank you for joining me today. Until next time, I’m Dr. Deb reminding you, your health is your responsibility, your choice, and your right. Be well, stay informed, fight back.and I’ll see you in the next episode. And if you’re looking for a full citation list of this episode, you can head over to letstalkwellnessnow.com and I will post all the citations for you so you have them in your arsenal as well. Thank you again.The post Episode 259 – The Desiccated Thyroid Crisis: FDA's Unseen Impact & Corporate Manipulation first appeared on Let's Talk Wellness Now.
VISPERAS DOMINGO DE RAMOSINVOCACIÓN INICIALV. Dios mío ven en mi auxilioR. Señor, date prisa en socorrerme. Gloria al Padre, y al Hijo, y al Espíritu Santo. Como era en el principio, ahora y siempre, por los siglos de los siglos. Amén.SALMODIASalmo 109 - Herido y Humillado, Dios lo exalto con su diestra.Salmo 113 B - La sangre de Cristo nos purificara, para dar culto al Dios vivo. Cántico - Cargando con nuestros pecados subió al leño, para que, muertos al pecado, vivamos para la justicia. REPONSORIO BREVEV. Te adoramos, oh Cristo, y te bendecimosR. Te adoramos, oh Cristo, y te bendecimosV. Porque por tu santa Cruz redimiste al mundo.R. Te adoramos, oh Cristo, y te bendecimosV. Gloria al Padre, y al Hijo, y al Espíritu SantoR. Te adoramos, oh Cristo, y te bendecimosCANTICO EVANGELICOAnt. “Dice la Escritura: “heriré al pastor y se dispersaran las ovejas del rebaño”, pero, después de mi resurrección, iré delante de vosotros a Galilea; allí me veréis, dice el Señor. Proclama mi almala grandeza del Señor,se alegra mi espíritu en Dios,mi salvador;porque ha mirado la humillaciónde su esclava.Desde ahora me felicitarántodas las generaciones,porque el Poderoso ha hechoobras grandes por mí:su nombre es santo,y su misericordia llega a sus fielesde generación en generación.Él hace proezas con su brazo:dispersa a los soberbios de corazón,derriba del trono a los poderososy enaltece a los humildes,a los hambrientos los colma de bienesy a los ricos los despide vacíos.Auxilia a Israel, su siervo,acordándose de la misericordia–como lo había prometido a nuestros padres–en favor de Abrahány su descendencia por siempre.Gloria al Padre, y al Hijo,y al Espíritu Santo.Como era en el principio,ahora y siempre,por los siglos de los siglos.Amén.PRECES“Santifica, Señor, al pueblo que redimiste con tu sangre.” CONCLUSIONV. El Señor nos bendiga, nos guarde de todo mal y nos lleve a la vida eterna.R. Amén.(192)
This month: Multiple FDA regulatory decisions germane to dermatology, psoriasis and lupus; and Eosinophilic Fasciitis (EF) reminder and should you worry about fibromyalgia? Show Notes: 1. FDA Approves Icotrokinra for Plaque Psoriasis The FDA approved an oral IL-23 inhibitor, icotrokinra (Icotyde), for use in moderate-to-severe plaque psoriasis in adults and children 12 years of age and older who are candidates for systemic therapy or phototherapy, according to a https://t.co/q5b3TceFHx 2. FDA has approved secukinumab (Cosentyx) for use pediatric patients (aged 12yrs) with moderate to severe hidradenitis suppurativa https://t.co/oX4LGU16QP 3. FDA has accepted the supplemental biologics license application for use of interleukin-23 inhibitor tildrakizumab (Ilumya; Sun Pharma) in active psoriatic arthritis (PsA) in adults. https://t.co/cwqz9DoWsL https://t.co/ut0A4MwqW7 4. TYK2 Inhibitor Deucravacitinib FDA Approved for Psoriatic Arthritis On Friday, March 6th, the FDA approved deucravacitinib (Sotyktu) for the treatment of adults with active PsA based on the results of the pivotal Phase 3 POETYK PsA-1 and POETYK PsA-2 clinical trials. https://t.co/a6rmortnoS 5.vUCB announced topline results of the BE-BOLD head-to-head study where bimekizumab (IL-17i) was superior to risankizumab (IL-23i) study; 553 active PsA in achieving an ACR50 response at 16 weeks. Enrolled PsA pts were either bilogic naïve or who had previous exposure to 1 TNFi 6. Retrospective TriNetX Network cohort study of adult PsA (N 123,031) pts, propensity- matched to non-PsA controls. PsA had signif higher CV morbidity: MACE (HR 1.74); mortality (HR 1.95); CHF (HR 1.96), MI (HR 1.71), & CVA (HR 1.49). bDMARDs reduced MACE (HR 0.95) & mortality (HR 0.92) vs csDMARDs https://t.co/bHrq9KpwBM 7. Prevalence of fibromyalgia in PsA = 18%. FM-PsA pts have higher scores Dz activity scores from FM, rather than inflammation. Fibromyalgia is assoc w/ worse disease outcomes, including failure to achieve low disease activity state and poorer response to therapy. https://t.co/utQRXPmpDs 8. JAMA Patient Education Page on JAMA Eosinophilic Fasciitis (EF). EF is rare, but begins with swelling and redness of the arms and/or legs. Later the skin thickens and develops the peau d' orange appearance. EF does not involve fingers or toes, & doesnt have Raynauds https://t.co/WEFFITtmQC 9. REVEAL, a 5-yr real-world study of 236 SLE pts initiating anifrolumab (basekbube SLEDAI-2K 7 for mucocutaneous (67%) & MSK (49%) dz. At 6 months, 26% achieved remission, 66% reached LLDAS, and 57% achieved LLDAS5. Authors claim rapid onset of action https://t.co/16OQatOcPj https://t.co/mU9aciCNcH 10. Update on FDA complete response letter to AZ regarding BLA hold for anifrolumab (Saphnelo) for SC use in SLE. CRL originally issued 10/10/25, but announced 2/3/26. FDA CRL cites critical data quality w/ key analyses in SC-TULIP study. A BLA decision expected in 1st half of 2026 https://t.co/zuwtsdL6I9 11. NEJM: Obinutuzumab in Active Systemic Lupus Erythematosus https://rheumnow.com/news/nejm-obinutuzumab-active-systemic-lupus-erythematosus
Co víme o lidech, kteří stojí za útokem na pardubickou zbrojovku? Proč se radikalizuje část propalestinského hnutí? A kdo po tomto činu dostal do rukou kladivo na vysoké školy a neziskovky? Ve Studiu N odpovídají reportéři Lukáš Prchal a Karolína Blažková. Celý díl najdete na herohero.co/studion
Und wieder ein Engel des Todes! Diesmal geht es um Charles Cullen, den wohl berüchtigten Todesengel in der US-amerikanischen Geschichte. Zugegeben hat er schon genug, aber es wird angenommen, dass er ~400 Menschen ermordet hat. Und dabei haben die Krankenhäuser, in denen er gearbeitet hat und die Polizei absolut super Arbeit geleistet. Nicht. Das war Sarkasmus. Sie haben ganz furchtbare Arbeit geleistet und es ihm ermöglicht, viel zu lange zu morden. In der heutigen Folge geht es um Überdosen, viel Bla bla und Charles Cullen. Wir sind übrigens weder Team Edward noch Team Jacob. Hoa hoa hoa... Wo ihr uns noch findet: https://todsicher.podcaster.de/ https://www.instagram.com/todsicherpodcast https://www.facebook.com/todsicherpodcast https://twitter.com/todsicherpod https://ko-fi.com/todsicherpodcast https://www.twitch.tv/paulaowl Quellen: https://murderpedia.org/male.C/c/cullen-charles.htm https://api.aerzteblatt.de/pdf/pp/6/9/s414.pdf https://www.onet.pl/informacje/thecrimespl/charles-cullen-mordowal-w-szpitalach-przez-16-lat/2hl9lmk,30bc1058 Musik von https://audiohub.de
This week I am back behind the controllers and in the mix and I will be spinning you some of the latest hottest Techno releases on a Raw Hypnotic tip. Expect to hear hot new released by top Artists such as Ben Klock and Fadi Mohem, Cari Lekebusch, IGLO, Anne, Oscar Escapa and Linear phase and lots more hot techno releases. ⚡️Like the Show? Click the [Repost] ↻ button so more people can hear it!
ईरान के साथ समझौत पर अमेरिका क्या बोला. पश्चिम एशिया में जंग पर क्या बोले पुतिन. ईरान में एक और धमाका. नेतन्याहू ने अब क्या कहा. ईरान में लड़कियों का सार्वजनिक अंतिम संस्कार. सीबीएसई ने पश्चिम एशिया में बोर्ड परीक्षा टाली. दुबई से वापस लौटे भारतीय. BLA का बड़ा दावा. स्मृति मंधाना बनी नंबर वन बल्लेबाज. सिर्फ 5 मिनट में सुनिए शाम 4 बजे तक की बड़ी ख़बरें.
The Derm on RheumNow podcast is a collection of Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, other CTD skin disorders. dermatology drugs, biiologics, JAKs - their use, efficacy and side effects. Features Dr. Jack Cush, Editor at RheumNow.com. SHOW NOTES FDA sent a complete response letter to AstraZeneca on their application (BLA) for anifrolumabs (Saphnelo) subcutaneous use in SLE. Despite a positive TULIP-SC trial & EU approval of SC-anifrolumab, FDA & sponsor still have to work things out. CRL reasons are unknown https://t.co/3dNwEyolrj Review of Calcinosis Cutis - Surgical intervent. most effective (excision, curettage, laser ablation, etc). Medical measures inconsistently, partially effective, best if used early & localized (CCB, TCN, probenecid, immunomodulation, biologics, colchicine, NA thiosulfate, & JAKi https://t.co/rv0hQBv6nX Systematic Review of Targeted Rx for Systemic Sclerosis: from 32 RCTs & 2036 pts Rx w/ 23 targeted agents. Guselkumab had greatest effect on mRSS, followed by tofacitinib, inebilizumab, & baricitinib. For FVC, B-cell Rx (belimumab, RTX) had highest efficacy https://buff.ly/vHOSRws Dermatomyositis outcomes w/ 2475 pts (claims) & 1196 pts (EHR). Half had myositis panels & 35% had + MSAbs. Steroid use common in 69% & 74%. HCQ, MTX, MMF. Outocmes (per 1000PYs) wereL all-cause hospitalisation 92, malignancy 15.3, ILD 6.4, and myocarditis 2.1 https://t.co/DJqKGNGX76 Danish DERMBIO registry of psoriasis pts Rx w/ biologics. Among 3790 bionaive pts ustekinumab had best 1-5 yr survival vs (ADA & SEC). In 3403 bioexperienced pts, bimekizumab, guselkumab, & risankizumab had highest 2-year drug survival rate. https://t.co/TInyLPMYkb Real-world study of 1202 #PsA pts shows that secukinumab retention rates were lower w/ smoking (79%/73%/72% in never/former/current smokers) but not w/ obesity (72%/77%/77% in normal/overweight/obese), Adh HR signif. higher w/ former (1.32) & current smokers (1.27) https://t.co/1REWmod73W Together PSO Trial - Combination Ixekizumab and Tirzepatide Today Lilly announced top line results of the TOGETHER-PsO open-label, Phase 3b trial demonstrating the significant benefits of concomitant ixekizumab (IXE: an IL-17A inhibitor) and tirzepatide (TIR: GLP-1agonist) over https://t.co/YWCjN2NyGM
Zvláštní rybářská povolenka podepsaná ministrem zemědělství otevírá cestu k volnému rybolovu bez obvyklých náležitostí. Rezort podle zákona může takové doklady vydávat v mimořádných případech. Jak se ale ukazuje, každý rok udělí prominentních povolení několik set. Kolik je mezi jejich držiteli politiků, státních úředníků a známých osobností? Za jakých okolností se k exkluzivním rybářským povolenkám dostali? A jak tento systém škodí běžným rybářům? Host: Vojtěch Blažek - investigativní reportér Seznam Zpráv Článek a další informace najdete na webu Seznam ZprávySledujte nás na sociálních sítích X, Instagram, Threads nebo Bluesky. Náměty a připomínky nám můžete psát na e-mail zaminutusest@sz.cz
Hello to our wonderful listeners and welcome back to another week of the Listen Local Podcas While Isaiah did great manning the ship last week, it was good to have the whole crew back for this one. On this week's show the guys caught up with Bill Bradford, the new owner of Brothers Motorsports. Among many other topics, the main thing they discussed was the 'why' factor. ·Why he decided to build a lake home in the BLA·Why this community means so much to him·Why he felt it was the perfect time to purchase Brothers Motorsports Plus... heck of a backstory and what led him to the BLA years ago. After Bill heads out, Colton, Jacob and Isaiah talk Local Happenings and News, which include:·Isaiah's friend - and singer at his wedding - becoming an overnight American Idol star·Brainerd Dance Team DOMINATING at State·An Olympic update as Jacob and BlazeAir prep their Italy trip to film with Minnesota's Paralympic Legend·Travel Perks taking home one of the top awards at the Explore Minnesota conference·Lakes Area Heroes Benefit update and much, much more...Once again, thanks so much to Bill Bradford for joining!And of course a HUGE thanks to our 2026 sponsors Pequot Lakes and Gull Lake Sanitation, Hanneken Insurance, Craguns Legacy Courses, Party Time Rental, Bens Marine and Motorsports and our PRESENTING SPONSOR Lakes Area CPAs!
Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let's dive into the latest updates impacting clinicians and healthcare providers like you!Interested in a more traditional, text rundown? Check out the HCPFive!Top 5 Healthcare Headlines for February 1-7, 2026:1. FDA Issues CRL to Dibutepinephrine (Anaphylm) Sublingual Film for Type 1 Allergic ReactionsThe FDA issued a Complete Response Letter for sublingual dibutepinephrine after identifying human factors issues that could compromise safe use during anaphylaxis, underscoring the importance of reliable administration in emergency settings.2. Positive Topline Data Released on Roflumilast Cream in Infants with Atopic DermatitisPhase 2 data indicate roflumilast cream was well tolerated in infants with atopic dermatitis and showed early signs of clinical improvement, supporting potential expansion of topical PDE4 inhibition into this very young population.3. FDA Accepts Resubmitted BLA for RelabotulinumtoxinA for Glabellar and Lateral Canthal LinesThe FDA accepted Galderma's resubmitted BLA for relabotulinumtoxinA following manufacturing process updates, allowing regulatory review to resume for treatment of glabellar and lateral canthal lines.4. Upadacitinib Regulatory Applications Submitted for Adults, Adolescents with VitiligoAbbVie submitted regulatory applications seeking to expand upadacitinib use to adults and adolescents with non-segmental vitiligo, positioning a systemic JAK inhibitor as a potential option for this underserved condition.5. VESPER-3: Positive Results of Long-Term GLP-1 PF'3944 in Overweight and Obesity Without T2DPositive phase 2b results suggest Pfizer's long-acting GLP-1 receptor agonist may support sustained weight management with extended dosing intervals in patients without diabetes.
Hi Listen Local fam! It is FINALLY warming up outside, and just in time for Crosslake Winterfest and other outdoor winter events happening in the BLA this weekend. On today's episode the crew catch up with Winterfest Committee Members Marlene Mingo and Heather Jones to chat about everything regarding the fun weekend in Crosslake, which actually kicks off Thursday! Also on this show, the guys recap the Extravaganza, Jacob's has a stay-cation at Breezy Point Resort, a snowmobile event at BIR this weekend, updates on the Lakes Area Heroes Banquet, the Olympics kicking off this week and much more! And HUGE thanks to our 2026 sponsors Pequot Lakes and Gull Lake Sanitation, Hanneken Insurance, Craguns Legacy Courses, Party Time Rental, Bens Marine and Motorsports and our PRESENTING SPONSOR Lakes Area CPAs! Instagram: ListenLocalMNBlazeAirProductionsWoodsToWaterMNNorthwoodsAgent Facebook:Listen Local MNBlazeAirMNWoodsToWaterMN
Arnar Eggert Thoroddsen, tónlistar- og félagsfræðingur og aðjúnkt við Háskóla Íslands, Freyja Steingrímsdóttir, stjórnmálafræðingur og framkvæmdastjóri Blaðamannafélags Íslands, og Vilborg Ása Guðjónsdóttir, alþjóðastjórnmálafræðingur, ræddu meðal annars um mótmæli í Bandaríkjunum vegna framgöngu ICE, áhrif samfélagsmiðla og áskoranir fjölmiðla á tímum gervigreindar, ásælni Bandaríkjaforseta í Grænland og stöðuna í Íran. Umsjón: Alma Ómarsdóttir Tæknimaður: Jón Þór Helgason
Hello to our wonderful Listen Local Listeners! On today's show we catch up with the man who has been to the ends of the earth and back, with stories that could match the "most interesting man in the world," Mr. Ben Nestrud. Backstories truly are the best, which make the guest segments so fun each time we have a new person on. In Ben's case we talk about all of the different lives he's lived - for lack of better term - and what led him to the Brainerd Lakes Area to settle down and start Ben's Marine and Motorsports. Plus, hear how he "rescued" the Listen Local Mobile Studio a few weeks back, and has since become the official "mobile repair guy" of the Listen Local Podcast! Thanks so much to Ben for coming in and telling his story which includes everything from his life in Okinawa, Japan with the Marines to testing the waters of MMA to landing right here in the BLA (with many stops along the way) and why he feels he found his "home" right here in Breezy Point, MN. After the guest segment, Ben sticks around to chat with the crew for their Local Happenings segment which include talk about Crosby's (and Minnesota's) new scoring champ, this weekend's Antique Snowmobile Rendezvous, a Chick-Fil-A update, and a big Fleet Farm announcement. Tune in for it all! And HUGE thanks to our 2026 sponsors Pequot Lakes and Gull Lake Sanitation, Hanneken Insurance, Craguns Legacy Courses, Party Time Rental and our PRESENTING SPONSOR Lakes Area CPAs! Instagram: ListenLocalMNBlazeAirMNWoodsToWaterMNNorthwoodsAgent Facebook:Listen Local MNBlazeAirMNWoodsToWaterMN
Speciál s nově zvoleným předsedou ODS Martinem Kupkou. O tom, jestli bude jako doposud každý předseda ODS někdy premiérem. Jaké byly největší chyby vlády a ODS v posledních letech. Jestli měl Stanjura s Blažkem odejít dřív a jestli Petr Fiala trváním na konsensu za každou cenu nezmrazil život ve straně. Jak chce zapojit příznivce a veřejnost do rozhodování ve straně a jestli pro ně budou otevřeny i primárky. Jaké budou nově povolené frakce v ODS a jaká bude jejich úloha v tvorbě politiky a spousta dalších témat, která čekají nového předsedu.
Samtökin Blaðamenn án landamæra (Reporters sans frontières) segja að 67 blaðamenn, hið minnsta, hafi verið drepnir á síðasta ári, Flestir þeirra féllu á Gaza fyrir hendi Ísraelshers. Bandaríkjastjórn hefur lýst því yfir að annað þrep vopnahléssamkomulags á Gaza hafi tekið gildi. Samkvæmt því eiga Hamas-samtökin að afvopnast og Ísraelsher að draga sig enn frekar frá Gaza. Þá skal alþjóðleg nefnd taka við stjórn á Gaza og fjölþjóðlegt friðargæslulið sjá þar um öryggi. Í lok Heimsgluggans var rætt um fund utanríkisráðherra Danmerkur og Grænlands með bandarískum ráðamönnum um Grænland. Ákveðið var að viðræðum yrði haldið áfram en Bandaríkjaforseti heldur til streitu kröfum um bandarísk yfirráð á Grænlandi.
//The Wire//2300Z December 4, 2025////ROUTINE////BLUF: ENOCH BURKE INDEFINITELY JAILED IN IRELAND. J6 PIPE BOMBER ALLEGEDLY IDENTIFIED.// -----BEGIN TEARLINE------International Events-Ireland: Yesterday Enoch Burke was sentenced to an indefinite prison term as the culmination of a long-standing scandal comes to a head. Burke was initially arrested for refusing to use a transgender person's pronouns during his job as a teacher back in 2022. Burke did not bow to this agenda, and desired to continue his job of being a medical teacher as he had done for many years. This snowballed into a gargantuan legal battle over the past few years, which has culminated in his termination from employment. He has been imprisoned several times since this scandal first began years ago.The court cleared him of speech crimes some time ago, but the school was able to find a judge who would help them ban him from the school grounds, but more specifically hold him indefinitely as long as he resisted their efforts to make him cave to their demands, namely that he use the pronouns. Burke has continually tried to return to his job and physically enter the school to continue teaching (attempts which have been regular over the past few years), but this has now been shut down due to him being arrested and held in jail indefinitely.Analyst Comment: This situation is obviously a longer saga that has been developing for some time. Burke, desiring to continue his work and return to the time before one student tried to ruin his life, has dug his heels in and turned activist, using his situation as an example of the sheer mental illness that has become enshrined in all facets of society. At this point, the two issues are now merged (the trespassing and the pronoun use). Burke is being indirectly targeted in this way because of his views on the transgender agenda, and the only way they could bag him was to get him for trespassing while he tries to continue his profession that was stable before the insanity began.Now, it seems that the proverbial final hill has been arrived at (maybe). Burke will be held in prison indefinitely as long as he refuses to cave to the trans agenda, and whatever fantastical charges they can come up with will be applied if he doesn't do so. Right now, he's effectively been sentenced to life in prison for contempt of court as this Irish-standoff situation will continue for as long as he holds out. All of the pro-trans mainstream media are quick to "Fact Check" this situation, even though the persecution is clear as day. If Burke were to cave to the insanity, the trespassing charges would be dropped, and he would immediately be re-employed without question, even if nothing more than to serve as a reminder that the insane ideologies of the day will break anyone. So far, however, Burke has not broken and he will be in prison for what is likely to be a very, very long time because of it (unless the situation changes due to national outrage, which has been building).-HomeFront-Washington D.C. - This afternoon, the infamous J6 pipe bomber was allegedly identified as Brian Cole Jr. of northern Virginia. A raid was conducted at Cole's home, which resulted in his arrest.-----END TEARLINE-----Analyst Comment: This case is probably one of the most sketchy situations to come to light regarding the entire J6 fiasco, and this is a massive can of worms that has been debated endlessly over the past few years. As a bit of backstory, for the longest time, the general theory was that the J6 pipe bomber was a government agent of some kind, as evidenced by the wealth of Congressional testimony involved in the years after the incident. There were a lot of suspect things that day, but the pipe bomber story smelled like the classic clandestine shenanigans that occur within the Beltway, so that was the assumption for the longest time. Last month, The Bla
© 2020-2026 Ivy Podcast Discovery LLC
